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1. Abbreviations 
 
BCR – B-cell receptor 
CREB – cAMP response element-binding protein 
DAG - Diacylglycerol 
4E-BP – 4E-binding protein  
EGFR – Epidermal growth factor receptor 
Erk – Extracellular signal-regulated kinase 
FGF – Fibroblast growth factor 
FOXO – Forkhead box class O transcription factor 
FRS2 – Fibroblast growth factor receptor substrate 2 
GAP – GTPase activating protein  
GPCR – G-protein coupled receptor  
GEF – Guanine nucleotide exchange factor 
GSK-3 – Glycogen synthase kinase-3  
HGF – hepatocyte growth factor 
HMG-CoA – 3-Hydroxy-3methylglutaryl CoA  
IGF-IR – Insulin-like growth factor-I receptor 
IP3 – Inositol 1,3,5-trisphosphate 
IRS – Insulin receptor substrate 
JNK – c-Jun N-terminal kinase 
MAPK – Mitogen-activated protein kinase 
mTOR – Mammalian target of rapamycin 
PDGFR – Platelet-derived growth factor receptor  
PDK1 – Phosphoinositide-dependent kinase-1 
PH – Pleckstrin homology 
PI3K – Phosphoinositide 3-kinase 
PI – Phosphatidylinositol  
PI(4)P – Phosphatidylinositol 4-monophosphate  
PI(3)P – Phosphatidylinositol-3-monophosphate 
PI(4,5)P2 – Phosphatidylinositol-4,5-bisphosphate 
PI(3,4)P2 – Phosphatidylinositol-3,4-bisphosphate  
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PI(3,4,5)P3 or PIP3 – Phosphatidylinositol-3,4,5-trisphosphate 
PKB – Protein kinase B (also termed Akt) 
PKC – Protein kinase C 
PLC – Phospholipase C 
PTB – Phosphotyrosine-binding  
PTEN – Phosphatase and tensin homolog deleted on chromosome 10 
RTK – Receptor tyrosine kinase 
SCF – Stem cell factor 
Shc – Src-homology collagen protein  
S6K – Ribosomal protein S6 kinase 
SH2 – Src homology region 2 
SHIP – SH2-containing inositol-5-phosphatase  
TCR – T-cell receptor 
TLR – Toll-like receptor 
TSC – Tuberous sclerosis complex 
 7
2. Summary 
The articles presented here report results from studies aimed at investigating the role of 
phosphoinositide 3-kinase (PI3K) signaling in cellular responses downstream of receptor 
tyrosine kinases (RTKs) in human cancer cells. The first step was the cloning and 
functional characterization of a distinct isoform of the PI3K family, termed PI3KC2β 
(Article I). This enzyme belongs to the Class II of PI3Ks based on sequence homology 
and substrate specificity in vitro. Hallmarks of Class II PI3Ks are a C-terminal 
phospholipid-binding C2 domain and an in vitro substrate specificity restricted to 
phosphatidylinositol (PI) and phosphatidylinositol 4-phosphate (PI(4)P). PI3KC2β was 
functionally distinguished from class I and III PI3K isoforms by the fact that it could 
catalyze phosphate transfer reactions in the presence of Ca2+ instead of Mg2+. Moreover, 
unlike the closely related PI3KC2α it is sensitive to nanomolar concentrations of the 
PI3K inhibitor wortmannin. In contrast to class I PI3Ks, Ras did not appear to regulate 
the activity of PI3KC2β. A novel function for the C-terminal C2 domain as a negative 
regulator of the catalytic activity of PI3KC2β could be established (Article I).  
The regulation of the class II PI3KC2α and PI3KC2β was then studied in order to 
elucidate their activation mechanisms in cells. Both enzymes were rapidly recruited to 
signaling complexes containing the epidermal growth factor receptor (EGFR) and Erb-B2 
upon cell stimulation with EGF (Article II) in human carcinoma-derived A431 cells. It 
was also found that PI3KC2β associated with the activated platelet-derived growth factor 
receptor (PDGFR) in fibroblasts. The use of EGFR phosphotyrosine point mutants 
established that preferentially associated with the Tyr992 and Tyr1068 residues of the 
EGFR cytoplasmic domain. The N-terminal region of PI3KC2β (residues 1 to 331) was 
demonstrated to be able to interact with the activated EGFR (Article II). 
In a subsequent study, it was shown that different human small cell lung 
carcinoma (SCLC) cell lines over-express distinct subsets of class IA and II PI3Ks, which 
results in striking differences in the signaling cascades activated by stem cell factor 
(SCF). Over-expression of class IA p85/p110α in SCLC cells increased SCF-stimulated 
protein kinase B (PKB) activation and cell growth, but did not affect extracellular signal-
regulated kinase (Erk) or glycogen synthase kinase-3 (GSK-3). This effect was selective, 
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since it was not observed in SCLC cell lines over-expressing p85/p110β or p85/p110δ. c-
Kit, the receptor for SCF associated with both class IA p85 and class II PI3KC2β, and 
both enzymes contributed to SCF-stimulated PKB activity. A dominant-negative 
PI3KC2β blocked both PKB activation and SCLC cell growth in response to SCF. 
(Article III). 
In the next report, we demonstrated that class II phosphoinositide 3-kinase C2β 
(PI3KC2β) associates with the Eps8/Abi1/Sos1 complex and is recruited to the EGFR as 
part of a multi-protein signaling complex also involving Shc and Grb2. Increased 
expression of PI3KC2β stimulated Rac activity in A-431 epidermoid carcinoma cells, 
resulting in enhanced membrane ruffling and migration speed of the cells. Conversely, 
expression of dominant negative PI3KC2β reduced Rac activity, membrane ruffling, and 
cell migration. Moreover, PI3KC2β -over-expressing cells were protected from anoikis 
and displayed enhanced proliferation, independently of Rac function. Taken together, 
these findings suggest that PI3KC2β regulates the migration and survival of human tumor 
cells by distinct molecular mechanisms (Article IV). 
In the last report, the impact of the 3-hydroxy-3methylglutaryl CoA (HMG-CoA) 
reductase inhibitor simvastatin on human SCLC cell growth and survival was 
investigated. Simvastatin profoundly impaired basal and growth factor-stimulated SCLC 
cell growth in vitro and induced apoptosis. SCLC cells treated with simvastatin were 
sensitized to the effects of the chemotherapeutic agent etoposide. Moreover, SCLC 
tumour growth in vivo was inhibited by simvastatin. These responses correlated with the 
inhibition of SCF-stimulated activation of Erk, PKB and ribosomal protein S6 kinase 
(S6K) by simvastatin. Constitutive activation of the Erk pathway was sufficient to rescue 
SCLC cell from the effects of simvastatin. The drug did not directly affect activation of c-
Kit or its localization to lipid rafts, but in addition to its ability to block Ras membrane 
localization, it selectively down-regulated H-Ras protein levels at the post-translational 
level. Down-regulation of either H- or K-Ras by RNA interference (RNAi) did not impair 
Erk activation by growth factors, whereas an RNAi specific for N-Ras inhibited 
activation of Erk, PKB and SCLC cell growth. Together our data demonstrate that 
inhibiting Ras signaling with simvastatin potently disrupts growth and survival in human 
SCLC cells (Article V). 
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3. Introduction 
3.1 Receptor tyrosine kinases 
3.1.1 Discovery of RTKs and mechanism of action 
A great variety of membrane-spanning cell surface receptors has been identified in the 
past 30 years and classified based on ligand preference, their primary structure and the 
induction of biological responses. Two well characterized types of cell surface receptors 
are G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Protein 
tyrosine kinases (PTKs) are enzymes endowed with an intrinsic protein kinase activity 
that catalyzes the transfer of γ-phosphate of ATP to tyrosine residues of protein substrates 
[1]. Protein tyrosine phosphorylation was discovered more than 25 years ago [2] and 
PTKs, the signaling pathways they activate, as well as the molecular mechanisms 
underlying their action and regulation have been extensively studied. The RTK class of 
cell surface receptors is one large family of membrane-spanning PTKs that contain that 
contain an N-terminal extracellular ligand-binding domain and a C-terminal intracellular 
tyrosine kinase domain [3, 4]. RTKs are central components of cell signaling networks 
and play a crucial role in normal physiological processes such as in embryogenesis and 
development. RTK networks control fundamental cellular activities including cell 
proliferation and survival, cell cycle control, metabolism, as well as cell shape and 
movement. They are able to detect, filter, and process a variety of environmental and 
intercellular factors. The importance of understanding the complexity of RTK signaling 
networks, their regulation and the RTK interconnections has been highlighted by a large 
variety of molecular alterations and deregulations found in various human diseases, 
including cancer.  
More than 50 mammalian RTKs have been identified so far including the well 
known insulin receptor (IR), Fms-like tyrosine kinase 3 (FLT3), c-Kit (the receptor for 
stem cell factor), epidermal growth factor receptor (EGFR), platelet derived growth 
factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), colony-stimulating 
growth factor I receptor (CSF-IR) and insulin-like growth factor I receptor (IGF-IR) [5]. 
A plethora of ligands such as peptides, proteins, lipids, or carbohydrates bind to and 
regulate the pleiotropic actions of RTKs. Tight control of the receptor activity is 
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maintained by protein-tyrosine phosphatases, by other serine/threonine kinases, as well as 
auto-regulatory mechanisms in the receptors. The binding of a specific ligand to the 
extracellular domain of the RTK induces conformational alterations that are transmitted 
across the plasma membrane, resulting in the activation of its intracellular tyrosine kinase 
activity [6]. Most RTKs exist as inactive monomers and form dimers following binding 
to their ligands, the vast majority of which are soluble peptides.  In general, ligand 
binding induces allosteric interactions causing dimerization of receptor subunits through 
disulfide-bridges [7] and autophosphorylation of specific tyrosine residues within their 
cytoplasmatic domains [6, 8]. Dimerization-mediated receptor activation mechanisms 
have been described for receptors composed of multimeric structures such as the IR, IGF-
IR, PDGFR and the EGFR.  
 
3.1.2 RTK signaling  
Dimerization of a RTK induces receptor activation and the autophosphorylation of 
tyrosine residues in its intracellular domain that serve as specific binding sites for 
proteins that contain Src-homology 2 (SH2) or phosphotyrosine binding (PTB) domains. 
Src homology-2 (SH2) [9] or phosphotyrosine-binding (PTB) [10] domains are known 
phosphotyrosine-recognition domains present in various signaling proteins. Proteins 
recruited to the activated RTK typically fall into two categories: enzymes whose activity 
is stimulated by the activated receptor (e.g., Src, PLC , Shp-2 and PI3K) and adaptors 
that contain additional protein interaction motifs (e.g., Grb2 and Shc). Many activated 
RTKs also engage a third group of molecules collectively known as docking proteins 
(e.g., IRS, FRS and the Gab/Dok proteins). Docking proteins are often recruited to the 
RTK via an intrinsic PTB domain or through an interaction with the Grb2 adaptor. These 
proteins also contain a membrane targeting motif (either a pleckstrin homology (PH) 
domain or a myristoylation site) and multiple tyrosine phosphorylation sites that can 
interact with additional binding partners. Thus, through the receptor itself, adaptors and 
docking proteins, numerous signaling components are recruited to the cell surface, 
thereby activating the repertoire of effector cascades required for a specific response. 
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Several well characterized signaling pathways downstream of the EGFR involve 
the Grb2 and the Src-homology collagen protein (Shc) isoforms as adapter molecules. 
The adapter proteins bind to the phosphotyrosine residues within the juxtamembrane 
region of the cytoplasmatic receptor and undergo subsequent tyrosine phosphorylation. 
The Grb2 and Shc adapters recruit the Sos guanine nucleotide exchange factor (GEF) to 
the plasma membrane. Sos in turn stimulates GDP to GTP exchange on Ras, leading to 
activation of the Raf/MEK/Erk (p42/44 MAPK) cascade [11] (Figure 1). The 
phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is activated by binding of the 
PI3K enzyme to the activated EGFR (Figure 1). The PI3K phosphorylate 
phosphatidylinositol (PI) on the D-3 position of the inositol ring, producing distinct 
second messengers such as PI(3,4,5)P3 (PIP3) [12] (Figure 2). These lipid products 
activate signal transduction by a cascade of proteins including phosphoinositide-
dependent kinase-1 (PDK1), protein kinase B (PKB)/Akt, forkhead transcription factors 
(FOXO), glycogen synthase kinase-3 (GSK-3), tuberous sclerosis complex 1 and 2 
(TSC1, TSC2), BAD, Ras homologue enriched in the brain (Rheb), mammalian target of 
rapamycin (mTOR), 4E-binding protein (4E-BP) and ribosomal protein S6 kinase (S6K) 
[12, 13](Figure 3). Other signaling pathways activated by the EGFR include 
phospholipase Cγ (PLCγ), which generates the second messengers diacylglycerol (DAG) 
and inositol 1,3,5-trisphosphate (IP3), activating signaling through protein kinase C 
(PKC) and intracellular Ca2+ (Figure 1). Generally, signals transduced through those 
signaling cascades have pleiotropic effects on cell behavior controlling cell proliferation, 
differentiation and cell migration, as well as apoptosis.  
 12
Figure 1. Simplified overview of EGFR signaling events 
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3.2 Signal transduction by the Ras super-family protein of GTP-binding proteins 
3.2.1 Ras proteins and their effectors 
The Ras GTPase is a key signaling molecule that allows RTKs to signal to the 
extracellular signal-activated kinase (Erk) cascade. Activation of all RTKs stimulates the 
exchange of GTP for GDP on Ras, and this nucleotide exchange allows Ras to interact 
directly with its target effectors, one of which is the initiating kinase of the Erk cascade, 
Raf [14]. The best-characterized route of Ras activation occurs at the plasma membrane 
and is mediated by the Sos guanine nucleotide exchange factor [15]. Sos is recruited from 
the cytosol to the plasma membrane as a result of its constitutive interaction with Grb2, 
whose SH2 domain can bind phosphotyrosine sites located on one or more of the 
following molecules: the activated RTK itself, Shc (another adaptor protein that binds 
activated RTKs via its PTB domain) or one of the membrane-localized docking proteins. 
The human Ras superfamily consists of three members: H-Ras, K-Ras and N-Ras, whose 
activity is regulated by cycling between an inactive GDP-bound and an active GTP-
bound state [16, 17]. Activated Ras transduces extracellular signals to diverse 
intracellular pathways, such as the PI3K or MAPK pathways, leading to cell survival, 
proliferation, differentiation, actin reorganization, vesicular trafficking, and gene 
expression, depending on cell types [18, 19]. Ras proteins represent some of the most 
frequently mutated oncogenes in human tumours [20-22]. In cancer, mutated or over-
expressed Ras is insensitive to inactivation by GTPase-activating proteins (GAPs) and 
therefore becomes constitutively activated [23]. This aberrant activation of Ras promotes 
tumourigenesis by facilitating all aspects of the malignant transformation of cancer cells, 
including cellular proliferation, transformation, invasion and metastasis [24, 25]. 
3.2.2 Rho and Rac signaling 
Like the majority of Ras superfamily proteins, most Rho/Rac GTPases behave as 
‘‘molecular switches’’ that fluctuate between inactive and active states, two 
conformations that depend on the binding of either GDP or GTP to the GTPases, 
respectively [26, 27]. Two types of regulatory proteins control this cycling: guanine 
nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). GEFs 
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promote the exchange of GDP for GTP on Rho/Rac, thereby producing the activation of 
these proteins during signal transduction [26, 27]. GAPs stimulate the hydrolysis of the 
bound GTP molecules, thus allowing the transfer of the GTPase back to the inactive state 
at the end of the stimulation cycle [26, 27]. In the GTP-bound state, these GTPases bind 
to a large collection of effector molecules that, in turn, lead to the stimulation of signaling 
cascades that promote general cellular responses, such as cytoskeletal change, 
microtubule dynamics, vesicle trafficking, cell polarity and cell cycle progression [26, 
28]. 
 
3.3 Phosphoinositide 3-kinase 
3.3.1 Discovery of PI3K and mechanism of action 
The phosphoinositide 3-kinases (PI3K) are a family of evolutionary conserved lipid 
kinases, playing a crucial role in controlling a wide variety of intracellular signaling 
events. PI3Ks phosphorylate phosphatidylinositol (PI) on the D-3 position of the inositol 
ring, producing distinct second messengers such as PI(3)P, PI(3,4)P2 and PI(3,4,5)P3 
(PIP3) [12] (Figure 2). These lipid products are known to activate diverse target proteins 
involved in complex signaling cascades, ultimately resulting in the activation of cellular 
activities comprising cell growth, proliferation, survival and motility.  
PI3K was first described 20 years ago as a distinct enzymatic activity associating 
with activated receptor tyrosine kinases (RTKs), such as the platelet-derived growth 
factor receptor (PDGFR) or with the polyoma virus middle T protein/pp60(c-src)  
complex [29-32]. PI3K activity was found to be elevated after cellular transformation by 
p60(v-src) [33] or abl [34]. After biochemical purification [35], the fist genes encoding 
the bovine catalytic p110α and regulatory p85α/β subunits of PI3K were cloned [36-39]. 
PI3K was shown to bind to activated RTKs via interaction of the Src homology-2 (SH2) 
domains of the p85 subunit to specific phosphotyrosine residues in the cytoplasmic 
domains of RTKs [37-44]. PI3K was then shown to be recruited to a broad variety of 
activated RTKs, including c-Met [45-47], c-Kit [48, 49], insulin-like growth factor-I 
receptor (IGF-IR) [50-52], insulin receptor (IR)/insulin receptor substrate-1 (IRS-1) [53-
56],  HER2/Neu/ErbB-2 [57], ErbB-3 [58-60], PDGFR [61, 62], Trk [63-65], and Flt3 
[66].  
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Constitutively activated RTKs were found to be associated with PI3K, such as for 
c-Kit in leukemia [67], Tpr-Met [68] and EGFRvIII [69]. The constitutively activated 
BCR-ABL tyrosine kinase fusion protein which has been shown to be an essential step in 
the pathogenesis of Philadelphia chromosome (Ph)-positive leukemias also associates 
with PI3K [70]. In addition, PI3K interacts with Ras and is directly activated by Ras 
binding to p110 [25, 71, 72]. PI3K activation by RTKs such as the PDGFR was also 
reported to be regulated by Ras [73]. It was also shown that p85 contains a GTPase-
responsive domain and an inhibitory domain, which together form a molecular switch 
that regulates PI3K [74]. H-Ras and Rac1 activate PI3K by targeting the GTPase-
responsive domain [74]. The stimulatory effect of these molecules, however, is blocked 
by the inhibitory domain, which functions by binding to tyrosine-phosphorylated 
molecules and is neutralized by tyrosine phosphorylation [74]. The complementary 
effects of tyrosine kinases and small GTPases on the p85 molecular switch result in 
synergy between these two classes of molecules toward the activation of the PI3K/Akt 
pathway [74]. Another study showed that p85 inhibits p110 activation by Ras [75]. This 
blockage was released by Tyr kinase stimulation, showing that the classical mechanism 
of class IA PI3K stimulation mediated by Tyr kinases also regulates Ras-induced PI3K 
activation [75]. At the same time as the genes of PI3K were cloned, it was shown that 
stimulation of cells with polypeptide growth factors such as PDGF induced the synthesis 
of novel second messengers phosphatidylinositol-3,4,5-trisphosphate (PIP3) and 
phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) [76, 77], which were resistant to the 
action of phospholipase C (PLC) [78].  
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Figure 2. Simplified model of the reaction catalyzed by PI3K and the activation of 
downstream signaling 
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3.3.2 PI3K isoforms 
A family of PI3K isoforms was subsequently cloned and characterized [13, 79, 80]. 
These enzymes are subdived in three classes (I-III), based on sequence homology and in 
vitro substrate specificity (overview in Table 1). The class IA of PI3K includes p85α/β 
and distinct regulatory subunits including mouse p55PIK [81], and splice variants of the 
p85α gene such as p55α [82], p50α [83], human p55γ [84]. Moreover, in addition to 
p110α distinct catalytic p110 isoforms were cloned and termed p110β [85] and p110δ 
[86, 87].  
 G-protein-coupled receptors (GPCRs) were shown to activate the generation of 
PIP3 [88, 89], through the activation of a distinct isoform of PI3K. This distinct class IB 
p110 isoform is activated by Gβγ subunits [90] and was termed p110γ [91, 92]. The 
p110γ isoform associates with an adaptor molecule (p101) contributing to its regulation 
by Gβγ subunits [92]. It should be also noted that the p110β isoform of class IA PI3K has 
also been reported to be regulated by Gβγ [93]. Ras activates p110γ at the level of the 
membrane, by allosteric modulation and/or reorientation of the p110γ, implying that Ras 
can activate p110γ without its membrane translocation [94]. This view is supported by 
structural work that has suggested binding of Ras to p110γ results in a change in the 
structure of the catalytic pocket [95]. 
A separate class II of PI3Ks was identified in Drosophila and mammalian cells, 
which is characterized by a C-terminal C2 domain and a substrate specificity restricted to 
PI and PI(4)P in vitro [96-100]. This family includes the human PI3KC2α, PI3KC2β and 
PI3KC2γ isoforms [101-104]. 
These class III PI3Ks are homologues of  the yeast VPS34 gene product (Vps34p) 
[105], which forms a complex with theVps15 protein kinase and is essential for protein 
sorting to the yeast lysosome-like vacuole [106]. The human homologues of Vps34p and 
Vps15p were subsequently cloned [107, 108], as well as their Drosophila counterpart 
[109]. The human Vps34p was reported to associate with the trans-Golgi network, a key 
site for the formation of transport vesicles destined for different intracellular 
compartments [110].  
 18
A family of protein kinases with homology to PI3Ks was also cloned and 
characterized, including yeast target of rapamycin (TOR) proteins [111, 112], and their 
mammalian homologue FRAP/RAFT1/mTOR [113-116]. This family of protein kinases 
also includes ATM, the gene product that is mutated in the autosomal recessive disorder 
ataxia telangiectasia (AT) [117, 118], ATR, and DNA-dependent protein kinase (DNA-
PK) [119]. 
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Table 1. Main characteristics of the mammalian PI3K isoforms 
Class Subclass Catalytic 
subunit 
Adaptor/ 
Regulatory
subunit 
Regulation Tissue 
distribution
In vitro 
Lipid 
products 
Functions 
I A p110α p85α, 
p85β 
p55α, 
p55γ 
p50α 
RTK, 
Ras 
Ubiquitous PI(3)P 
PI(3,4)P2 
PI(3,4,5)P3 
Development 
Cancer 
Myocardial 
contractility 
 
  p110β p85α, 
p85β 
p55α, 
p55γ 
p50α 
RTK, 
GPCR 
Ras 
Ubiquitous PI(3)P 
PI(3,4)P2 
PI(3,4,5)P3 
Development 
Insulin 
signal. 
Motility 
Phagocytosis 
Thrombosis 
  p110δ p85α, 
p85β 
p55α, 
p55γ 
p50α 
RTK, 
Ras 
Leukocytes PI(3)P 
PI(3,4)P2 
PI(3,4,5)P3 
Immunity 
Cytokine 
signal. 
B-cell dev.+ 
migr. 
T-cells dev. 
BCR+TCR 
sign. 
Neutrophil 
migr. +burst. 
 B p110γ p101, 
p84/p87 
GPCR Myeloid PI(3)P 
PI(3,4)P2 
PI(3,4,5)P3 
Thymocyte 
dev. 
T cell dev. 
and migr. 
Neutrophil 
migr. +burst. 
Macrophage 
migr. 
Myocardial 
contractility 
II  C2α clathrin RTK, 
GPCR 
integrin 
Ubiquitous PI(3)P 
PI(3,4)P2 
 
Insulin 
signal. 
Vesicle traf. 
Cell surv. 
SM contract. 
  C2β Grb2,  
clathrin 
RTK, 
GPCR 
integrin 
Ubiquitous PI(3)P 
PI(3,4)P2 
Vesicle traf. 
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3.3.3 Class II PI3K isoforms 
The class II of PI3Ks was first identified in Drosophila and mammalian cells and is 
characterized by a C-terminal C2 domain and a substrate specificity restricted to PI and 
PI(4)P in vitro [96-100]. This family includes the human PI3KC2α, PI3KC2β and 
PI3KC2γ isoforms [101-104]. A variety of cell surface receptors have been shown to 
activate class II PI3Ks, including activated integrins in platelets [120]. It was found that 
activation of PKBα/Akt in platelets is phosphorylation-dependent and biphasic [121]. 
The initial phase is PI(3,4,5)P3-dependent and more efficient, whereas the second phase 
depends upon PtdIns(3,4)P2 generated after aggregation [121]. In this system PI(3,4)P2 is 
generated by transient formation of PtdIns3P and generation of PI(3,4)P2, the latter 
primarily by PI(3)P 4-kinase. This novel pathway and the activation of PKB/Akt are 
inhibited by the PI3K inhibitor, wortmannin, and the calpain inhibitor, calpeptin, 
constituting the first evidence that PtdIns(3,4)P2 can stimulate PKB/Akt in vivo in the 
absence of PtdIns(3,4,5)P3 [122]. Integrin-activated generation of the second messenger 
PtdIns(3,4)P2 thus depends upon a route distinct from that known to be utilized initially 
by growth factors. 
PI3KC2α was shown to be constitutively associated with phospholipid 
membranes and that in contrast to the class IA PI3K enzymes, PI3KC2α could be co-
purified with a population of clathrin-coated vesicles (CCVs) [123, 124]. The distribution 
of PI3KC2α closely paralleled that of markers of the trans-Golgi and the trans-Golgi 
network (TGN) [123]. Futher work showed that clathrin functions as an adaptor for the 
PI3KC2α, binding to its N-terminal region and stimulating its catalytic activity, 
especially toward phosphorylated inositide substrates [125]. Furthermore, it was shown 
that endogenous PI3KC2α is localized in coated pits and that exogenous expression 
affects clathrin-mediated endocytosis and sorting in the trans-Golgi network [125]. 
Another study explored the behavior of novel cytoplasmic clathrin-coated structures 
containing PI3KC2α and clathrin [126]. These structures were found to exhibit localized, 
rapid mobility, which is micro-tubule-based [126]. Dynactin was shown to mediate the 
movement of these clathrin-PI3KC2α structures and an interaction between endogenous 
PI3KC2α and dynactin subunits was demonstrated [126]. Together, these results reveal a 
 21
molecular linkage between PI3KC2α and the microtubule motor machinery, with 
implications for membrane trafficking in intact cells [126]. Another study demonstrated 
that the isolated clathrin binding domain of PI3KC2α can drive clathrin lattice assembly 
and that both it and the lipid kinase activity of the protein can independently modulate 
clathrin distribution and function when expressed in cells [127]. Together, these results 
suggest that PI3KC2α employs both protein-protein interaction and localized production 
of 3-phosphoinositides to affect clathrin dynamics at sites of membrane budding and 
targeting [127]. 
The crystal structure of the PI3KC2α C2 domain was determined in [128]. 
Structural studies reveal that the C2 domain has a typical anti-parallel beta-sandwich fold 
[128]. The surface of this C2 domain displayed three small, shallow sulfate-binding sites 
[128]. Site-directed mutagenesis revealed that this C2 domain binds specifically to 
PI(3,4)P2 and PI(4,5)P2 and that three lysine residues are responsible for the phospholipid 
binding affinity [128]. The crystal structure of the PI3KC2α PX domain, which binds 
PI(4,5)P2 was reported in [129]. This PX domain was shown to contain a signature PI-
binding site that is optimized for PI(4,5)P2 binding [129]. Furthermore, the PX domain 
displayed significantly higher PI(4,5)P2 membrane affinity and specificity when 
compared with the PI3KC2α C2 domain [129]. 
It was also demonstrated that PI3KC2α has dual cellular localization present in 
the cytoplasm and in the nucleus [130]. A distinct nuclear localization signal sequence 
was identified in a stretch of 11 amino acids located within C2 domain of the kinase 
[130]. Phosphorylation of PI3KC2α was induced by inhibition of RNA polymerase II-
dependent transcription and coincides with enlargement and rounding up of the nuclear 
speckles [130]. The results suggest that phosphorylation of PI3KC2α is inversely linked 
to mRNA transcription and supported the importance of phosphoinositides for nuclear 
activity [130]. In another study cell cycle-dependent and genotoxic stress-induced 
phosphorylation of PI3KC2α was investiagated [131]. It was found that the kinase 
becomes phosphorylated upon exposure of cells to UV irradiation and in proliferating 
cells at the G2/M transition of the cell cycle [131]. Stress-dependent and mitotic 
phosphorylation of PI3KC2α occured on the same serine residue (Ser259) within a 
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recognition motif for proline-directed kinases [131]. Mitotic phosphorylation of 
PI3KC2α was attributed to Cdc2 activity, and stress-induced phosphorylation of 
PI3KC2α was mediated by JNK/SAPK [131]. The protein level of PI3KC2α was 
regulated by proteolysis in a cell cycle-dependent manner and in response of cells to 
stress [131]. Phosphorylation appears to be a prerequisite for proteasome-dependent 
degradation of PI3KC2α and may therefore contribute indirectly to the regulation of the 
activity of the kinase [131]. 
Another study investigated the involvement of PI3KC2α in vascular smooth 
muscle cell migration [132]. PI(3)P and PI(3,4)P2 were increased upon smooth muscle 
cell migration but their synthesis was affected only partially by the PI3K inhibitors, 
wortmannin and LY294002 [132]. Measurement of PI3KC2α demonstrated its activation 
upon smooth muscle cell migration [132]. Moreover, PI3KC2α was found to be 
differentially regulated by α(v)β(3) and α(v)β(5) integrin engagement [132]. 
Another study found that KCl and noradrenaline induced stimulation of PI3KC2α 
in a Ca2+-dependent manner, but not class IA PI3K in vascular smooth muscle (VSM) 
cells [133]. Down-regulation of PI3KC2α expression by siRNA inhibited contraction and 
phosphorylation of the regulatory subunit of myosin phosphatase (MYPT1) and myosin 
light chain [133]. Intravenous wortmannin infusion induced sustained hypotension in rats, 
with inhibition of PI3KC2α activity, GTP-loading of Rho and MYPT1 phosphorylation 
in the artery [133]. These results indicate the novel role of PI3KC2α in Ca2+-dependent 
Rho-mediated negative control of myosin phosphatase and thus VSM contraction [133]. 
Insulin caused a rapid increase in the activity of PI3KC2α in CHO-IR cells, 3T3-
L1 adipocytes, and fully differentiated L5L6 myotubes [134]. This suggested that insulin-
induced phosphorylation could play a role in regulation of the activity of PI3KC2α [134]. 
The finding that insulin activates PI3KC2α in cell types known to possess a wide range 
of responses to insulin suggests that PI3KC2α is a novel component of insulin-stimulated 
signaling cascades [134]. It was demonstrated that PI3KC2α and PI3KC2β represent two 
downstream targets of the activated epidermal growth factor (EGF) receptor in human 
carcinoma-derived A431 cells [135]. Stimulation cells with EGF or PDGF resulted in the 
rapid recruitment of both enzymes to a phosphotyrosine signaling complex that contained 
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the activated RTKs [135]. It was thus concluded that class II PI3K enzymes may 
contribute to the generation of 3' phosphoinositides following the activation of 
polypeptide growth factor receptors in vivo and thus mediate certain aspects of their 
biological activity [135]. Proline-rich motifs within the N terminus of PI3KC2β were 
shown to mediate the association of this enzyme with activated EGFR and that this 
interaction involves the Grb2 adaptor [136]. Another study showed that different human 
small cell lung carcinoma (SCLC) cell lines over-express distinct subsets of class IA and 
II PI3Ks, which resulted in striking differences in the signaling cascades activated by 
stem cell factor (SCF) [137]. Over-expression of class IA p85/p110α in SCLC cells 
increased SCF-stimulated protein kinase B (PKB) activation and cell growth [137]. c-Kit 
associated with both class IA p85 and class II PI3KC2β, and both enzymes contributed to 
SCF-stimulated Akt activity [137]. A dominant-negative PI3KC2β blocked both Akt 
activation and SCLC cell growth in response to SCF [137]. It was shown that in renal 
cells there is a spatial separation of the inositol lipid signaling system between basal-
lateral plasma membranes (BLM) and brush-border plasma membranes (BBM), and that 
HGF causes activation of PLC and PI3K primarily in BLM, which leads to calpain-
mediated activation of PI3KC2β in BBM with a concomitant increase in PI(3)P [138]. 
Another report showed that, in the membrane-depleted liver nuclei during the 
compensatory liver growth, there is an increase in PI(3)P formation as a result of 
PI3KC2β activation, which may be a calpain-mediated event [139]. The activity of 
nuclear PI3KC2β was investigated in HL-60 cells blocked at the G(1)/S boundary and 
allowed to progress synchronously through the cell cycle [140]. The activity of 
PI3KC2β in the nuclei and nuclear envelopes showed peak activity at 8 h after release 
from the G(1)/S block, which correlates with G(2)/M phase of the cell cycle [140]. 
Further work showed calpain-mediated activation of the nuclear PI3KC2β during G(2)/M 
phase of the cell cycle in HL-60 cells [140]. 
It was shown that lysophosphatidic acid (LPA) stimulates the production of 
PI(3)P through activation of PI3KC2β [141]. Both PI(3)P and PI3KC2β were involved in 
LPA-mediated cell migration in human cancer cell lines [141]. Another study found that 
cell motility is increased in cells over-expressing PI3KC2β [142]. In addition, 
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overexpression of PI3KC2β transiently decreased cell adhesion and expression of α4β1 
integrin subunits [142]. It was shown that PI3KC2β is present in lamellipodia of motile 
cells [142]. Cortical actin staining increased and actin rich lamellipodia and filopodia 
became evident upon overexpression of PI3KC2β [142]. Overexpression of a FYVE 
domain fusion protein abolished this response demonstrating that the effect of 
overexpression of PI3KC2β on the reorganization of actin filaments is dependent upon 
PI(3)P [142]. Finally, overexpression of PI3KC2β increased GTP loading of Cdc42 
[142]. Another study demonstrated that PI3KC2β associates with the Eps8/Abi1/Sos1 
complex and is recruited to the EGF receptor as part of a multi-protein signaling complex 
also involving Shc and Grb2 [143]. Increased expression of PI3KC2β stimulated Rac 
activity in A-431 epidermoid carcinoma cells, resulting in enhanced membrane ruffling 
and migration speed of the cells [143]. Conversely, expression of dominant negative 
PI3KC2β reduced Rac activity, membrane ruffling, and cell migration. Moreover, 
PI3KC2β -over-expressing cells were protected from anoikis and displayed enhanced 
proliferation, independently of Rac function [143].  
To study the role for PI3KC2β in tissue, transgenic mice over-expressing the 
enzyme in both suprabasal and basal epidermal layers were generated [144]. These mice 
lacked epidermal abnormalities [144]. Mice deficient in PI3KC2β were then generated by 
targeted gene deletion [144]. PI3KC2β knockout mice were viable and fertile and 
displayed normal epidermal growth, differentiation, barrier function, and wound healing 
[144]. To exclude compensation by PI3KC2α, RNAi was then used to knock down both 
PI3KC2α and PI3KC2α in epidermal cells simultaneously [144]. Induction of 
differentiation markers was unaffected in the absence of PI3KC2α and PI3KC2α [144]. 
These findings indicated that class II PI3Ks are not essential for epidermal 
differentiation. 
 
3.3.4 Signal transduction by PI3K 
The use of mutant receptors defined for the first time a role for PI3K in PDGF-dependent 
DNA synthesis, and established PI3K as an independent downstream mediators of 
PDGF's mitogenic signal [145]. Furthermore, a mutant CSF-1R with a mutation in the 
 25
PI3K-binding site had impaired ability to transduce signals controlling changes in 
morphology and increased cell growth [146]. The PI3K binding sites also appeared both 
necessary and sufficient for the normal endocytic trafficking of the activated PDGFR 
[147]. A PDGFR mutant in which both p85-binding sites were mutated failed to stimulate 
membrane ruffling and chemotaxis, suggesting a role for PI3K in these responses [148, 
149].  
Pharmacological inhibitors of PI3K were instrumental in elucidating the role of 
the enzyme in cellular signaling events. These inhibitors include quercetin analogs, the 
most widely used being LY294002 [150], as well as the microbial product wortmannin 
[151-153]. In addition to their effects on PI3K isoforms, LY294002 and wortmannin also 
inhibit the activity of the related kinases such as mTOR [154], ATM and DNA-PK [155]. 
Studies with wortmannin and LY294002 uncovered a role for PI3K in activation of 
p70(S6K) by insulin and PDGF [156-159], as well as in the inactivation of glycogen 
synthase kinase-3 (GSK-3) [160]. Subsequently, PI3K was shown to be essential in the 
activation of the proto-oncogene Akt (or protein kinase B (PKB)) by PDGF [161] and 
other growth factors [162, 163]. These results were confirmed by the observation that 
transfection of membrane-targeted p110 was sufficient to trigger downstream responses 
characteristic of growth factor action, including the stimulation of p70(S6K) and Akt 
[164, 165]. The phospholipids products of PI3K, initially PI(3,4)P2, were shown to 
directly activate Akt by binding to its pleckstrin homology (PH) domain [166, 167]. PH 
domains were recognized to be modular domains with the ability to specifically bind to 
the lipid products of PI3K, including PIP3 [168]. PI3K activity was also required for 
phosphorylation of both Thr308 and Ser473 activation sites of Akt [169]. The kinase that 
phosphorylates Akt was then purified, cloned and shown to phosphorylates Akt1 at 
Thr308 and increases its activity [170-172]. It was found that only PI(3,4,5)P3 or 
PI(3,4)P2 were effective in potently activating the kinase, which was termed PI(3,4,5)P3-
dependent protein kinase-1 (PDK1) [170]. PDK1 is the protein kinase that mediates the 
activation of Akt/PKB by insulin and growth factors [173]. PDK1 therefore plays a key 
role in mediating many of the actions of the second messengers produced by PI3K. In 
response to PDGF, binding of PI(3,4,5)P3 and/or PI(3,4)P2 to the PH domain of PDK-1 
causes its translocation to the plasma membrane where it co-localises with Akt/PKB, 
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significantly contributing to the scale of Akt/PKB activation [173, 174] (Figure 2-3). The 
identification of the kinase that phosphorylates the Akt Ser473 was achieved only in the 
last few years [175]. The complex of the mammalian target of rapamycin (mTOR) and 
Rictor was shown to be essential for this crucial phosphorylation step in Akt by several 
groups [175, 176].  
In addition to its role in Akt activation, PDK1 was also shown to be responsible 
for the regulation of other protein kinases [177, 178]. PDK1 phosphorylated the 
activation loop sites of PKCζ and PKCδ in vitro and in a PI3K-dependent manner in vivo 
[179, 180]. Several members of the PKC family tested formed complexes with PDK1 
[179]. Serum and glucocorticoid-inducible kinase (SGK) was also shown to be a target of 
PI3K/PDK1 [181, 182]. A regulatory link between p70(S6K) and PDK1 was also 
described, since PDK1 selectively phosphorylate and activated p70(S6K) in vitro and in 
vivo [183, 184].  
In addition, PI3K was reported to be involved in the activation of several other 
protein kinases, including c-Jun N-terminal kinase (JNK) by EGF [185]. Bruton's 
tyrosine kinase (Btk), which has a PH domain that can bind PIP3 [186], was described as 
a downstream target of PI3K (p110γ) [187]. Etk/Bmx a member of the Btk tyrosine 
kinase family that contains a PH domain is also involved in the PI3K pathway [188].  The 
Tec family non-receptor tyrosine kinases were shown to be regulated by PIP3 interacting 
with its PH domain [189]. Activation of PI3K caused phospholipase C-γ (PLC-γ) PH 
domain-mediated membrane targeting and PLC-γ activation [190, 191]. Integrin-linked 
kinase (ILK) was also proposed to be a receptor-proximal effector for the PI3K-
dependent, extracellular matrix and growth factor mediated, activation of Akt, and 
inhibition of GSK-3 [192]. RNA interference (RNAi) as well as conditional knock-out of 
ILK had no effect on phosphorylation of Akt on Thr-308 but resulted in almost complete 
inhibition of phosphorylation on Ser-473 and significant inhibition of Akt activity, 
accompanied by significant stimulation of apoptosis [193]. In addition, Raf-1 activation 
by Ras was shown to be achieved through a combination of both physical interaction and 
indirect mechanisms involving the activation of PI3K as a second Ras effector, which 
directs p21-activated kinase (PAK)-mediated regulatory phosphorylation of Raf-1 [194]. 
Phosphorylation of Raf-1 on Ser338 through PI3K and Pak was also shown to provide a 
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co-stimulatory signal which together with Ras leads to strong activation of Raf-1 kinase 
activity by integrins [195]. 
A consensus sequence which predicts high-affinity binding of PH domains to 
PtdIns(3, 4)P2 and/or PtdIns(3,4,5)P3 was proposed, and several new PH domain-
containing proteins that directly bind PI3K products were identified, including Gab1, 
Dos, myosinX, and Sbf1 [196], GAP1(m) a member of the GAP1 family of Ras GTPase-
activating proteins (GAPs) [197], DAPP1 [198], Tec family tyrosine kinases [199], 
ARAP3 [200], and  P-Rex1, a Rac activator [201].  
 
3.3.5 PI3K /Akt signaling and apoptosis 
The involvement of PI3K in prevention of apoptosis by polypeptide growth factor 
receptors was first described by studies using both wortmannin and LY294002 [202-204]. 
Experiments with pharmacological inhibitors, as well as expression of wild-type and 
dominant-inhibitory forms of Akt, demonstrated that Akt mediates PI3K-dependent 
survival [205-209]. These findings were supported by studies showing that Ras activation 
of PI3K suppresses c-Myc-induced apoptosis through the activation of Akt but not 
p70(S6K) [210]. UV-B light-induced-apoptosis was also prevented by IGF-I/PI3K/Akt 
signaling [211] and interleukin-3-dependent survival of hematopoietic cells required 
PI3K/Akt signaling [212]. Neuronal survival in the absence of nerve growth factor (NGF) 
was promoted by PI3K/Akt [213] and it was also shown that Akt can transduce a survival 
signal for differentiating neuronal cells through a mechanism that is independent of 
induction of Bcl-2 or Bcl-XL, or inhibition of JNK activity [214]. PI3K acting through 
Akt was implicated as a key mediator of the aberrant survival of Ras-transformed 
epithelial cells in the absence of attachment, and as a mediator of matrix-induced survival 
of normal epithelial cells [215].  
Some of the proposed mechanisms for the antiapoptotic effect of activated Akt 
include the inhibition of proapoptotic Bcl-2 family proteins, downregulation of death 
receptors, and enhancement of the glycolytic rate [216]. There exists a large panel of Akt 
substrates which mediate its effects on cellular responses, including apoptosis, growth 
and cell cycle regulation [207-209] (Figure 1). The Akt targets identified so far include 
BAD [217-219], the FOXO (Forkhead Box, subgroup O)  family of transcription factors 
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[220-223] and AFX [224], glycogen synthase kinase-3 (GSK-3) [173, 225, 226], 
p27(Kip1) [227, 228], Mdm2 [229], endothelial NO synthase (eNOS) [230, 231], cyclic 
nucleotide phosphodiesterase 3B isoform (PDE3B)[232], Raf [233 , 234], apoptosis 
signal-regulating kinase 1 (ASK1) [235], androgen receptor (AR)[236], the nuclear factor 
CREB [237], the p300 transcriptional coactivator [238], E2F [239, 240].  
In addition, it was shown that Akt can regulate signaling pathways that lead to 
induction of the NF-κB family of transcription factors [241-243]. This induction occurred 
at the level of degradation of the NF-κB inhibitor IκB [241]. PDGF was also shown to 
activate NF-κB through Ras and PI3K to Akt and the IκB kinase (IKK) [242]. Upon 
PDGF stimulation, Akt transiently associated in vivo with IKK and induced IKK 
activation [242]. Akt was reported to stimulate NF-κB predominantly by up-regulating of 
the transactivation potential of the p65 subunit of NF-κB [244]. Survivin, a member of 
the inhibitors-of-apoptosis gene family, is expressed in a cell-cycle-dependent manner in 
all the most common cancers but not in normal differentiated adult tissues [245]. 
Hematopoietic cytokines were reported to exert their antiapoptotic and mitogenic effects, 
at least in part, by increasing survivin levels, which was dependent on PI3K [245]. It was 
also shown that both vascular endothelial growth factor (VEGF) and basic fibroblast 
growth factor significantly reduce the pro-apoptotic potency of chemotherapy on 
endothelial cells, a response, which PI3K-dependent and could be recapitulated by over-
expressing the dominant-active form of Akt [246]. Work by others showed that the anti-
apoptotic effects of IL-6 were mediated, at least in part, by Mcl-1 (Bcl-2 family member) 
expression and that the response occured mainly through the PI3K/ Akt pathway [247]. It 
was reported that apoptotic cell death of PTEN-deficient prostate cancer cells induced by 
LY294002 or expression of wild type PTEN can be abrogated by disrupting Fas/Fas 
ligand (FasL) interactions [248]. These data showed that apoptosis induced by blockade 
of the PI3K pathway in prostate tumor cells is mediated by an autocrine Fas/FasL 
apoptotic mechanism and the Fas apoptotic pathway is both necessary and sufficient to 
mediate apoptosis by PI3K inhibition [248]. 
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3.3.6 PI3K signaling and growth control 
Signaling networks that promote cell growth are frequently dysregulated in cancer. One 
regulatory network, which converges on effectors such as eIF4E-binding proteins-1 (4E-
BP1) and p70(S6K), leads to growth by promoting protein synthesis [249]. In particular, 
a tumor suppressor complex whose function is lost in tuberous sclerosis patients regulates 
the nutrient signal carried by the critical signaling protein TOR to the effectors 4E-BP1 
and p70(S6K)[249].  
It was initially demonstrated that the PI3K/Akt signaling pathway, in concert with 
FRAP/mTOR, induces the phosphorylation and inactivation of the translational repressor, 
the 4E-BP1 [250] and activation of p70(S6K) [251, 252]. Further work showed that 
mTOR signals downstream to at least two independent targets, S6K1 and 4E-BP1/eIF4E 
that function in translational control to regulate mammalian cell size [253]. The tuberous 
sclerosis complex-2 (TSC2) gene product, tuberin, is as a target of Akt [254-257]. 
Normal cellular functions of hamartin and tuberin, encoded by the TSC1 and TSC2 tumor 
suppressor genes, are closely related to their direct interactions. Tuberous sclerosis (TSC) 
is an autosomal dominant disorder characterized by the formation of hamartomas in a 
wide range of human tissues [258]. It was demonstrated that, upon activation of PI3K, 
tuberin is phosphorylated on consensus recognition sites for PI3K-dependent S/T kinases 
[254]. Moreover, Akt/PKB could phosphorylate tuberin in vitro and in vivo [254]. It was 
also shown that S939 and T1462 of tuberin are PI3K-regulated phosphorylation sites and 
that T1462 is constitutively phosphorylated in PTEN (-/-) tumor-derived cell lines [254]. 
Finally, a tuberin mutant lacking the major PI3K-dependent phosphorylation sites 
blocked the activation of S6K1, suggesting a means by which the PI3K-Akt pathway 
regulates S6K1 activity [254]. Another report showed that TSC1-TSC2 inhibits the 
p70(S6K) and activates the 4E-BP1, which was mediated by inhibition of mTOR [254, 
256]. Furthermore, TSC2 was shown to be directly phosphorylated by Akt. TSC2 was 
inactivated by Akt-dependent phosphorylation, which destabilizes TSC2 and disrupts its 
interaction with TSC1 [256]. It was shown that TSC1 and TSC2 antagonize the amino 
acid-TOR signaling pathway [255]. TSC1 and TSC2 could physically associate with 
TOR and function upstream of TOR genetically. In Drosophila melanogaster and 
mammalian cells, loss of TSC1 and TSC2 resulted in a TOR-dependent increase of S6K 
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activity [259]. Furthermore, although S6K is normally inactivated in animal cells in 
response to amino acid starvation, loss of TSC1-TSC2 renders cells resistant to amino 
acid starvation. It was thus proposed that the TSC1-TSC2 complex antagonizes the TOR-
mediated response to amino acid availability [259]. These studies identified TSC1 and 
TSC2 as regulators of the amino acid-TOR pathway and provide a new paradigm for how 
proteins involved in nutrient sensing function as tumor suppressors [255, 259]. Work by 
another group showed that insulin or IGF-I stimulated phosphorylation of tuberin, which 
was inhibited by the PI3K inhibitor LY294002 [260]. Expression of constitutively active 
PI3K or active Akt induced tuberin phosphorylation. It was further demonstrated that 
Akt/PKB associates with hamartin-tuberin complexes, promoting phosphorylation of 
tuberin and increased degradation of hamartin-tuberin complexes [260]. The ability to 
form complexes, however, was not blocked. Akt also inhibited tuberin-mediated 
degradation of p27(KIP1), thereby promoting CDK2 activity and cellular proliferation 
[260]. These results confirmed that tuberin is a direct physiological substrate of Akt and 
that phosphorylation of tuberin by PI3K/Akt is a major mechanism controlling hamartin-
tuberin function [260].  
Further work showed that TSC1/2 is a GAP for the small GTPase Rheb and that 
insulin-mediated Rheb activation is PI3K-dependent [261-263]. Rheb over-expression 
induced S6K1 phosphorylation and inhibited Akt phosphorylation, as did loss-of-function 
mutations in TSC1/2 [261]. Finally, co-expression of a human TSC2 harboring a disease-
associated point mutation in the GAP domain, failed to stimulate Rheb GTPase activity 
or block Rheb activation of S6K1 [261, 263]. A screen for novel regulators of growth 
identified Rheb (Ras homologue enriched in brain), a member of the Ras superfamily of 
GTP-binding proteins [262]. Increased levels of Rheb in Drosophila melanogaster 
promoted cell growth and alter cell cycle kinetics in multiple tissues. In mitotic tissues, 
overexpression of Rheb accelerates passage through G1-S phase without affecting rates 
of cell division [262]. Genetic and biochemical tests indicated that Rheb functions in the 
insulin signalling pathway downstream of TSC1-TSC2 and upstream of TOR [262]. In 
another study, mutations in the Drosophila melanogaster Rheb gene were isolated as 
growth-inhibitors, whereas over-expression of Rheb promoted cell growth [264]. Genetic 
and biochemical analyses suggest that Rheb functions downstream of the tumour 
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suppressors TSC1-TSC2 in the TOR signalling pathway to control growth, and that a 
major effector of Rheb function is S6K [264, 265]. 
It was reported that Akt activation causes proteasomal degradation of substrates 
that control cell growth and survival [266]. Expression of activated Akt triggered 
proteasome-dependent declines in the protein levels of the Akt substrates tuberin, 
FOXO1, and FOXO3a [266]. The addition of proteasome inhibitors stabilized the 
phosphorylated forms of multiple Akt substrates, including tuberin and FOXO proteins 
[266]. Activation of Akt also triggered the ubiquitination of several proteins containing 
phosphorylated Akt substrate motifs [266]. Together the data indicate that activated Akt 
stimulates proteasomal degradation of its substrates and suggest that Akt-dependent cell 
growth and survival are induced through the degradation of negative regulators of these 
processes [266]. It has been shown that FKHR is phosphorylated via insulin or growth 
factor signaling cascades, resulting in its cytoplasmic retention and the repression of 
target gene expression. Insulin treatment was shown to decrease endogenous FKHR 
proteins in HepG2 cells, which was inhibited by proteasome inhibitors [267]. FKHR was 
ubiquitinated in vivo and in vitro, and insulin enhances the ubiquitination in the cells 
[267]. In addition, the signal to FKHR degradation from insulin as shown to be mediated 
by the PI3K pathway, and the mutation of FKHR at the serine or threonine residues 
phosphorylated by Akt inhibited the ubiquitination in vivo and in vitro [267]. Another 
report showed that FoxO1 expression is constitutively suppressed in chicken embryo 
fibroblasts transformed by P3k or Akt [268]. In this system, phosphorylation-dependent 
degradation of FoxO1 by means of proteasomes played a role in oncogenic 
transformation by P3k and Akt [268]. 
It was shown that TSC1-TSC2 is required for insulin signaling to PI3K [269, 
270]. TSC1-TSC2 was required for insulin signaling to PI3K by restraining the activity of 
S6K1, which when activated inactivates insulin receptor substrate (IRS) function, via 
repression of IRS-1 gene expression and via direct phosphorylation of IRS-1 [269]. These 
results suggested that the low malignant potential of tumors arising from TSC1-2 
dysfunction may be explained by the failure of TSC mutant cells to activate PI3K and its 
downstream effectors [269, 270]. 
An overview of PI3K/Akt/mTOR signaling pathway is presented in Figure 3. 
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Figure 3. Simplified overview of the PI3K/Akt/mTOR signaling pathway. Proteins 
where mutations have been described in human cancer are depicted in bold. 
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3.3.7 PI3K in cell cycle control 
Cell cycle progression is a tightly controlled process. To initiate cell division, mitogens 
trigger a number of early signals that promote the G(0)-G(1) transition by inducing cell 
growth and the activation of G(1) cyclins. Activation of cyclin E/cdk2 (cyclin-dependent 
kinase 2) at the end of G(1) is then required to trigger DNA synthesis (S phase entry). 
Among the early signals induced by mitogens, activation of PI3K appears essential to 
induce cell cycle entry, as it regulates cell growth signalling pathways (see previous 
section), which in turn determine the rate of cell cycle progression. Another mechanisms 
by which PI3K and its downstream effector Akt regulate cell cycle entry is by 
inactivation of the FOXO transcription factors, which induce expression of quiescence 
genes such as those encoding p27(Kip), p130 and cyclin G2 [271]. PI3K/FOXO then 
work as a complementary switch: when PI3K is active, FOXO transcription factors are 
inactive [271]. The switch is turned on and off at different phases of the cell cycle, thus 
regulating cell cycle progression. Akt triggers a network that positively regulates G1/S 
cell cycle progression through inactivation of GSK3β, leading to increased cyclin D1, 
and inhibition of Forkhead family transcription factors and the tumor suppressor tuberin 
(TSC2), leading to reduction of p27(Kip1) [272]. The identification of p21Waf1/Cip1 
and p27Kip1 as novel substrates of Akt provided new insights into mechanisms whereby 
hyperactivation of this lipid signaling pathway may lead to cell cycle deregulation in 
human cancers [272]. 
The PI3K/Akt pathway must be activated in G1 to inactivate forkhead 
transcription factors and allow cell cycle entry. It was subsequently shown that 
attenuation of the PI3K/Akt pathway is required to allow transcriptional activation of 
FOXO in G2 [273]. FOXO activity in G2 controls mammalian cell cycle termination, as 
interference with FOXO transcriptional activation by disrupting PI3K/Akt 
downregulation, or by expressing a transcriptionally inactive FOXO mutant, induces cell 
accumulation in G2/M, defective cytokinesis, and delayed transition from M to G1 of the 
cell cycle [273]. It was demonstrated that FOXO regulate expression of mitotic genes 
such as cyclin B and polo-like kinase (Plk) [273]. These results supported the important 
role of forkhead transcription factors in the control of mammalian cell cycle completion, 
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and suggest that efficient execution of the mitotic programme depends on downregulation 
of PI3K/Akt and consequent induction of FOXO transcriptional activity [273]. 
 
3.3.8 PI3K signaling in migration and invasion 
Migration of cancer cells is one of the key factors responsible for cancer metastasis. The 
elucidation of mechanisms responsible for the highly invasive potential of cancer cells 
can help to identify specific targets for the treatment of cancer patients. Highly invasive 
cancers are usually characterized by aberrant activity of specific intra- or extracellular 
molecules such as protein kinases, phosphatases, transcriptional factors, proteolytic 
enzymes, and others. Therefore, inhibition of specific target molecules in common 
signaling pathway(s) responsible for metastatic spread can have potential clinical 
relevance.  
The first identified downstream target of PI3K in PDGF-stimulated membrane 
ruffling was Rac [274, 275]. Class IA PI3Ks are implicated in many cellular responses 
controlled by receptor tyrosine kinases (RTKs), including actin cytoskeletal remodeling. 
Within this pathway, Rac is a key downstream target/effector of PI3K. One possible 
candidate for this function is the Rac-activating complex Eps8-Abi1-Sos-1, which 
possesses Rac-specific guanine nucleotide exchange factor (GEF) activity [276]. It was 
shown that Abi1 (also known as E3b1) recruits PI3K, via p85, into a multimolecular 
signaling complex that includes Eps8 and Sos-1 [276]. The recruitment of p85 to the 
Eps8-Abi1-Sos-1 complex and PIP3, co-operate to unmask its Rac-GEF activity in vitro 
[276]. Moreover, they are indispensable for the activation of Rac and Rac-dependent 
actin remodeling in vivo [276]. Upon growth factor stimulation, endogenous p85 and 
Abi1 consistently colocalized into membrane ruffles, and cells lacking p85 failed to 
support Abi1-dependent Rac activation [276]. 
Direct PI3K activation was sufficient to disrupt epithelial polarization and induce cell 
migration and invasion [277]. PI3K inhibition also disrupted actin structures, suggesting 
that activation of PI3K alters actin organization, leading to increased motility and 
invasiveness [277]. Integrin-mediated activation of PI3K was shown to promote 
carcinoma invasion by targeting Rac [278]. Vav, a guanosine diphosphate (GDP)-
guanosine triphosphate (GTP) exchange factor (GEF) for Rac that stimulates the 
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exchange of bound GDP for GTP, bound to and was directly controlled by substrates and 
products of PI3K [279].  PI3K also acts upstream of Tiam1, an activator of Rac [280]. 
Akt/PKB potently promoted invasion of highly metastatic cells, by increasing cell 
motility and matrix metalloproteinase-9 (MMP-9) production, in a manner highly 
dependent on its kinase activity and membrane-translocating ability [281]. The increase 
in MMP-9 production was mediated by activation of NF-κB transcriptional activity by 
Akt/PKB [281]. However, Akt/PKB did not affect the cell-cell or cell-matrix adhesion 
properties of the cells. These findings thus established Akt/PKB as a major factor in the 
invasive abilities of cancer cells [281]. Another study showed that PI3K is constitutively 
active and controls cell motility of highly invasive breast cancer cells by the activation of 
transcription factor, NF-κB [282]. The urokinase-type plasminogen activator (uPA) 
promoter contains an NF-κB binding site, and uPA expression in MDA-MB-231 cells 
was induced by the constitutively active NF-κB [282]. Cell migration was inhibited by 
overexpression of a dominant negative p85α, as well as by pretreatment of cells with 
wortmannin and LY294002 [282]. Highly invasive MDA-MB-231 cells constitutively 
secreted uPA in amounts significantly higher than poorly invasive MCF-7 cells [282]. 
Furthermore, inhibition of NF-κB markedly attenuated endogenous migration, and 
inhibition of PI3K and NF-κB reduced secretion of uPA [282]. These data suggest a link 
between constitutively active PI3K, NF-κB, and secretion of uPA, which is responsible 
for the migration of highly invasive breast cancer cells [282]. In another study, 
constitutive activation of Akt was identified in breast cancer cells, while benign breast 
epithelial cell lines were immortalized through pathways that are independent of the 
EGF/PI3K/Akt kinase cascade, but this was not associated with invasiveness [283]. 
Transfection of constitutively active Akt caused accelerated cell division and osteopontin 
expression [283]. Conversely, dominant-negative Akt kinase slows cell cycle progression 
and suppresses osteopontin expression [283]. The manipulation of osteopontin expression 
in this setting by transfection of the gene or its antisense did not affect the growth rate of 
the cells but altered cell motility and anchorage independence [283]. Therefore, Akt 
kinase was postulated to activate two distinct genetic programs: the program of growth 
and survival and the program of invasiveness and anchorage independence, which is 
mediated by osteopontin [283]. These studies define Akt kinase as a molecular bridge 
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between cell cycle progression and dissemination. In colorectal cancer, another group 
investigated the effect of inhibiting the PI3K/Akt/IKKα pathway in regulating the 
inappropriate constitutive activation of NF-κB and β-catenin [284]. Inducible expression 
of either dominant-negative IKKα or PTEN strongly inhibited both the constitutive NF-
κB- and β-catenin-dependent promoter and endogenous gene activation [284]. Targeted 
array-based gene expression analysis of this inducible system reveals that many of the 
genes downregulated upon inhibition of this pathway were involved in tumor 
angiogenesis and metastasis [284]. 
 
3.3.9 Alterations in PI3K signaling in cancer 
We will first discuss the evidence describing altered PI3K signaling in human cancer, 
before more specifically addressing alterations in PTEN and PIK3CA. 
 
3.3.9.1 Activation of the PI3K/Akt signaling pathway in human cancer 
A first study showed that colorectal tumors exhibited enhanced PI3K activity compared 
with normal colonic mucosa, raising the possibility that PI3K may be a potential target 
for new strategies for the treatment of colorectal carcinoma [285]. In small cell lung 
cancer (SCLC) initial reports found high basal constitutive PI3K activity, which results in 
high basal Akt and ribosomal p70(S6K) activity [286]. Inhibition of PI3K activity 
markedly inhibited SCLC cell proliferation in liquid culture as a result of stimulating 
apoptosis and promoting cell cycle delay in G1[286]. Thus, constitutive PI3K activity in 
SCLC cells was proposed to play an important role in promoting the growth and 
anchorage independence of SCLC [286].  Another study identified Akt as a constitutively 
active kinase that promotes survival of NSCLC cells and demonstrated that modulation of 
Akt activity by pharmacological or genetic approaches alters the cellular responsiveness 
to therapeutic modalities such as chemotherapy or radiotherapy [287]. Elevated phospho-
Akt staining was reported in 65% human malignant mesotheliomas (MM) specimens 
[288]. In addition, Akt phosphorylation was consistently observed in MMs arising in 
asbestos-treated mice and in MM cell xenografts [288]. Treatment of a MM cell line with 
rapamycin resulted in growth arrest in G1 phase, while LY294002 in combination with 
 37
cisplatin had greater efficacy in inhibiting cell proliferation and inducing apoptosis than 
either agent alone [288].  
A report showed activation of Akt2 in human primary ovarian cancer and 
induction of apoptosis by inhibition of PI3K/Akt pathway [289]. The majority of tumors 
displaying activated Akt2 were high grade and stages III and IV [289].  Immunostaining 
and Western blot analyses using a phospho-Ser-473 Akt antibody that detects the 
activated form of Akt2 confirmed the frequent activation of Akt2 in ovarian cancer 
specimens [289]. Another study determined the frequency of Akt activation in ovarian 
cancer and found elevated staining (phosphor-Ser473) in 68% ovarian carcinomas [290]. 
In another report, significantly increased Akt1 kinase activity was detected in primary 
carcinomas of prostate, breast, and ovary [291]. The majority of Akt1-activated tumors 
were high grade and stage III/lV [291].  
In thyroid cancer, increased levels of phosphorylated total Akt were identified in 
follicular but not papillary cancers compared with normal tissue [292]. Levels of Akt1 
and Akt2 proteins and Akt2 RNA were elevated only in the follicular cancers [292]. In 
paired samples, Akt 1, 2, 3, and phospho-Akt levels were higher in cancers [292]. These 
data suggested that Akt activation may play a role in the pathogenesis or progression of 
sporadic thyroid cancer [292]. In head and neck cancer, a significant association was 
found between phospho-Akt staining and local recurrence in the patient series. Evaluation 
of PI3K activation by Akt phosphorylation was thus suggested to be a prognostic marker 
for response to therapy [293]. Immunohistochemical analyses in breast carcinomas 
revealed that elevated expression of HER-2/neu was found to correlate with over-
expression of Akt2 protein and activation of Akt kinase [294]. HER-2/neu-
overexpressing breast cancer cell lines were resistant to apoptosis induced by UV 
treatment and hypoxia, which was suppressed in the presence of the PI3K inhibitors 
LY294002 and wortmannin, indicating a link between Akt activation and stress resistance 
in HER-2/neu-overexpressing cells [294]. In colorectal carcinomas, 
immunohistochemical analysis showed that 46% of the tumors had a high level of 
expression of phosphorylated Akt with a close association with Ki-67 proliferative 
activity and the number of apoptotic bodies [295]. Akt phosphorylation was also 
correlated with clinicopathologic parameters of the malignancies, including depth of 
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invasion, infiltration to venous vessels, lymph node metastasis, and clinicopathologic 
stage [295]. It was concluded that activation of Akt plays an important role during the 
progression of colorectal carcinomas by helping promote cell growth and rescue cells 
from apoptosis [295].  
Another study suggested that PI3K has a major role in the control of proliferation 
and apoptosis of growth factor-independent multiple myeloma cell lines [296]. 
Constitutive activation of this pathway was shown to be a frequent event in the biology of 
multiple myeloma in vivo and may be more frequently observed in primary plasma-cell 
leukemia [296]. Purified plasmocytes from patients with myeloma or leukemia displayed 
constitutive phosphorylation of Akt, FKHRL-1 and p70(S6K), which was inhibited by 
LY294002 and enhanced by IGF-I [296]. Another study demonstrated that Akt is 
activated in AML blasts and that p70(S6K) and 4EBP-1, downstream mediators of Akt 
signaling, also are phosphorylated in AML blasts [297]. In a short-term culture system, 
most AML patient samples showed a dose-dependent decrease in survival after 
incubation with LY294002 [297]. Incubation of AML blasts with RAD001 induced only 
a small decrease in survival of the cells [297]. However, when combined with Ara-C, 
RAD001 enhanced the toxicity of Ara-C [297]. These results demonstrated that 
constitutive activation of the PI3K pathway is necessary for the survival of AML blasts 
and that targeting of this pathway with pharmacologic inhibitors may be of clinical 
benefit in treatment of AML [297]. Another study demonstrated that the overall survival 
of patients with the Akt phosphoryated on Ser473 was significantly shorter than that of 
patients without [298].  Thus, the detection of the Akt phosphorylation may provide a 
new tool for identifying AML patients at high risk of an unfavorable outcome [298]. 
Based on the observation that melanoma cell lines exhibit constitutive Akt 
activation, this event was evaluated by immunohistochemistry [299]. Normal and slightly 
dysplastic nevi exhibited no significant Akt expression, in marked contrast to the 
dramatic Akt immunoreactivity seen in severely dysplastic nevi and melanomas [299]. It 
was proposed that activation of Akt may be an early marker for tumor progression in 
melanoma [299]. 
In glioma, a study analysed the levels of expression of PI3K pathway members 
through quantitative Western analysis [300]. Levels of phospho-Akt, and phospho- 
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p70(S6K) were all found to be inversely associated with cleaved caspase-3 levels, 
suggesting PI3K pathway activation is associated with reduced levels of apoptosis [300]. 
Activation of PI3K pathway members was found to be significantly associated with 
reduced survival times [300].  
A study examined the status of activation of Akt in different stages of squamous 
cell carcinoma development in clinical samples from squamous carcinomas of the head 
and neck (HNSCC) patients [301]. By immunohistochemical analysis, it was 
demonstrated that activation of Akt is a frequent event in human HNSCC because active 
Akt could be detected in these tumors with a pattern of expression and localization 
correlating with the progression of the lesions [301]. In line with these observations, Akt 
was constitutively activated in a large fraction of HNSCC-derived cell lines [301]. 
Gefitinib, a specific epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor, was shown to have activity against approximately 10% of unselected non-
small-cell lung cancer (NSCLC) patients. An important finding was that patients with 
phosphorylated Akt-positive tumors who received gefitinib had a better response rate, 
disease control rate, and time to progression than patients with phosphorylated Akt-
negative tumors, suggesting that gefitinib may be most effective in patients with basal 
Akt activation [302]. 
 
3.3.9.2 The tumor suppressor gene PTEN 
Discovery of PTEN as an antagonist of the PI3K/Akt pathway 
The tumor suppressor called phosphatase and tensin homolog deleted on chromosome 10 
(PTEN) (or MMAC1) is located on human chromosome 10q23, and was initially 
described as sharing homology with the protein tyrosine phosphatase family [303, 304]. 
Germ-line mutations in PTEN give rise to several related neoplastic disorders, including 
Cowden disease [303, 305, 306]. It was demonstrated that over-expression of PTEN 
reduced insulin-induced PIP3 production in human cells without effecting insulin-induced 
PI3K [307]. Purified recombinant PTEN catalyzed dephosphorylation of PIP3, 
specifically at position 3 on the inositol ring [307]. These results established the function 
of PTEN as a phosphoinositide 3-phosphatase by regulating PIP3 levels [307]. Although 
more than half of PTEN mutations result in protein truncation, a significant fraction of 
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PTEN mutations are missense mutations. It was shown that the majority of PTEN 
missense mutations (90%) eliminated or reduced phosphatase activity towards inositol 
1,3,4,5-tetrakisphosphate and PIP3 [308]. It was reported that a missense mutation in 
PTEN, PTEN-G129E, which is observed in two Cowden disease kindreds, specifically 
ablates the ability of PTEN to recognize inositol phospholipids as a substrate, suggesting 
that loss of the lipid phosphatase activity is responsible for the etiology of the disease 
[309]. Furthermore, expression of wild-type or substrate-trapping forms of PTEN in 
mammalian cells altered the levels of the phospholipid products of PI3K and ectopic 
expression of the phosphatase in PTEN-deficient tumor cell lines resulted in the 
inhibition of PKB/Akt and regulation of cell survival [309]. It was also shown that 
glioblastoma cells, in contrast to primary human astrocytes, contain high endogenous Akt 
activity and high levels of PI(3,4,5)P3 and PI(3,4)P2, the lipid products of PI3K [310]. 
These glioblastoma cells were shown to express mutant forms of the 3' phospholipid 
phosphatase PTEN [310]. PTEN antagonized the activation of PKB/Akt by growth 
factors, by activated PI3K and by PDK1, but did not antagonize the phospholipid-
independent activation of PKB/Akt lacking the PH domain [310]. These results 
confirmed a role for PTEN in regulating the activity of the PI3K pathway in malignant 
human cells. Another study demonstrated that the acute administration of MMAC/PTEN 
in glioma cells infected with recombinant adenoviruses resulted in the inhibition of Akt-
mediated signaling, growth inhibition, and anoikis [311]. In another report, PTEN 
inhibited cell growth and/or colony formation in epithelial cell lines [312]. The decrease 
in cellular proliferation was associated with an induction of apoptosis and an inhibition of 
signaling through the PI3K pathway [312]. Akt/PKB was able to rescue cells from 
PTEN-dependent death [312]. PTEN expression potently suppressed the growth and 
tumorigenicity of human glioblastoma U87MG cells [313]. The growth suppression 
activity of PTEN was mediated by its ability to block cell cycle progression in the G1 
phase [313]. Such an arrest correlated with a significant increase of the cell cycle kinase 
inhibitor p27(KIP1) and a concomitant decrease in the activities of the G1 cyclin-
dependent kinases [313]. PTEN expression also led to the inhibition of Akt/PKB [313]. 
Further work implicated p27(KIP1) as a critical mediator of PTEN-induced G1 arrest 
[314]. It was also shown that PTEN protein induces a G1 block when reconstituted in 
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PTEN-null cells [315]. A PTEN mutant associated with Cowden's disease 
(PTEN;G129E) has protein phosphatase activity yet is defective in dephosphorylating 
inositol 1,3,4,5-tetrakisphosphate in vitro and fails to arrest cells in G1[315]. These data 
suggest a link between induction of a cell-cycle block by PTEN and its ability to 
dephosphorylate, in vivo, PIP3 [315]. In a parallel study, PTEN impaired activation of 
endogenous Akt in cells and inhibited phosphorylation of 4E-BP1 [316]. In addition, 
PTEN/MMAC1 repressed gene expression in a manner that is rescued by Akt but not 
PI3K [316]. Finally, higher levels of Akt activation are observed in human prostate 
cancer cell lines and xenografts lacking PTEN/MMAC1 expression when compared with 
PTEN/MMAC1-positive prostate tumors or normal prostate tissue [316].  
 
Animal models 
PTEN-mutant mouse embryos displayed regions of increased proliferation [317]. In 
contrast, PTEN-deficient immortalized mouse embryonic fibroblasts exhibited decreased 
sensitivity to cell death in response to a number of apoptotic stimuli, accompanied by 
constitutively elevated activity and phosphorylation of PKB/Akt [317]. Expression of 
exogenous PTEN in mutant cells restores both their sensitivity to agonist-induced 
apoptosis and normal pattern of PKB/Akt phosphorylation. Furthermore, PTEN 
negatively regulated intracellular levels of PIP3 in cells and dephosphorylates it in vitro 
[317]. These results showed that PTEN may exert its role as a tumor suppressor by 
negatively regulating the PI3K/PKB/Akt signaling pathway. The PTEN gene was shown 
to be fundamental for embryonic development in mice, as PTEN mutant embryos died by 
day 9.5 of gestation [318]. Heterozygous mice developed lymphomas associated with 
loss of heterozygosity of the wild-type PTEN allele, and tumor appearance was 
accelerated by gamma-irradiation [318]. These lymphomas had high levels of activated 
Akt/PKB [318]. This suggested that tumors associated with PTEN loss of heterozygosity 
may arise as a consequence of an acquired survival advantage [318]. When more than 6 
months old, PTEN (+/-) mice were shown to develop a range of tumors, partially 
resembling the spectrum of neoplasia observed in Cowden's syndrome patients [319]. 
One-half of PTEN (+/-) females developed breast tumors, whereas all of the females had 
endometrial hyperplasia, and there was a high incidence of endometrial cancer [319]. 
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Analysis of prostate cancer progression in transgenic adenocarcinoma of mouse prostate 
mice bred to PTEN (+/-)  heterozygous mice, coupled with analysis of the PTEN gene 
and protein in the resulting tumors, revealed that haploinsufficiency of the PTEN gene 
promotes the progression of prostate cancer in this model system [320]. Using the Cre-
loxP system, another group selectively inactivated PTEN in skin and prostate in mice 
[321]. Abnormalities in PTEN mutant skin consisted of mild epidermal hyperplasia, 
whereas prostates from these mice exhibited high-grade prostatic intraepithelial neoplasia 
that frequently progressed to focally invasive cancer [321]. These data demonstrated that 
PTEN is an important physiological regulator of growth in the skin and prostate [321]. 
Further, the early onset of prostatic neoplasia in PTEN mutant males implicated PTEN 
mutations in the initiation of prostate cancer. Consistent with high PTEN mutation rates 
in human prostate tumors, these data indicated that PTEN is a critical tumor suppressor in 
this organ. 
Primordial germ cells (PGCs), which are the embryonic precursors of gametes, 
are the source of testicular teratoma. To elucidate the intracellular signaling mechanisms 
that underlie germ cell differentiation and proliferation, mice with a PGC-specific 
deletion of the PTEN gene were generated [322]. Male mice that lacked PTEN exhibited 
bilateral testicular teratoma, which resulted from impaired mitotic arrest and outgrowth of 
cells with immature characters [322]. Experiments with PTEN-null PGCs in culture 
revealed that these cells had greater proliferative capacity and enhanced pluripotent 
embryonic germ cell colony formation [322]. PTEN thus appears to be essential for germ 
cell differentiation and an important factor in testicular germ cell tumor formation [322].  
In another study aimed at determining the role of the the PI3K pathway in 
pancreas development, a pancreas-specific knockout of PTEN was generated [323]. 
Knockout mice displayed progressive replacement of the acinar pancreas with highly 
proliferative ductal structures that contained abundant mucins and expressed markers of 
pancreatic progenitor cells [323]. Moreover, a fraction of these mice develop ductal 
malignancy [323]. Thus, misregulation of the PI3K pathway may contribute to the 
initiation of pancreatic carcinoma in vivo [323]. 
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Functional consequences of PTEN inactivation 
A null mutation was introduced into the mouse PTEN gene by homologous 
recombination in embryonic stem (ES) cells [324]. PTEN (-/-) ES cells exhibited an 
increased growth rate and proliferated even in the absence of serum. ES cells lacking 
PTEN function also displayed advanced entry into S phase [324]. This accelerated G1/S 
transition was accompanied by down-regulation of p27(KIP1), a major inhibitor for G1 
cyclin-dependent kinases [324]. Inactivation of PTEN in ES cells and in embryonic 
fibroblasts resulted in elevated levels of PIP3. Consequently, PTEN deficiency led to 
dosage-dependent increases in phosphorylation and activation of Akt/PKB and Akt 
activation increased Bad phosphorylation and promoted PTEN (-/-) cell survival [324]. 
Fas-mediated apoptosis was impaired in PTEN (+/-) mice, and T lymphocytes from these 
mice show reduced activation-induced cell death and increased proliferation upon 
activation. PI3K inhibitors restored Fas responsiveness in Pten (+/-) cells [325]. These 
results indicated that PTEN is an essential mediator of the Fas response and a repressor of 
autoimmunity and thus implicated PI3K/Akt pathway in Fas-mediated apoptosis [325]. 
PTEN was shown to suppress breast cancer growth through down-regulating 
PI3K signaling, which leads to the blockage of cell cycle progression and the induction of 
cell death in a sequential manner [326]. In breast cancer cells under anchorage-
independent conditions, PTEN also induced anoikis, a form of apoptosis that occurs when 
cells are dissociated from the extracellular matrix, which is enhanced in conjunction with 
low serum culture conditions [327]. Together, these data suggest that PTEN effects on 
the PI3K signaling cascade are influenced by the cell stimulatory context, and that 
depending on the exposure to growth factors and other exogenous stimuli such as integrin 
ligation, PTEN can induce cell cycle arrest, apoptosis or anoikis in breast cancer cells. 
The tumour suppressor activities of PTEN were linked to the machinery controlling cell 
cycle through the modulation of signaling molecules whose final target is the functional 
inactivation of the retinoblastoma gene product [328]. Expression of wild-type PTEN 
reduced the expression of cyclin D1 [329]. Cyclin D1 reduction was accompanied by a 
marked decrease in endogenous retinoblastoma (Rb) protein phosphorylation on cyclin 
D/CDK4-specific sites, showing an early negative effect of PTEN on Rb inactivation. 
PTEN expression also prevented cyclin D1 from localizing to the nucleus during the 
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G(1)- to S-phase cell cycle transition [329]. The PTEN-induced localization defect and 
the cell growth arrest could be rescued by the expression of a nucleus-persistent mutant 
form of cyclin D1, indicating that an important effect of PTEN is at the level of nuclear 
availability of cyclin D1 [329]. Furthermore, in human glioblastoma cells, PTEN 
mutation can cooperate with EGFR activation to increase VEGF mRNA levels by 
transcriptionally up-regulating the proximal VEGF promoter via the PI3K/Akt pathway 
[330]. In addition, the ability of PTEN to potently inhibit H-Ras-induced morphological 
transformation and anchorage-independent growth in NIH3T3 cells was reported [331]. It 
was also shown that PTEN can regulate prostate cancer cell proliferation and apoptosis 
through inhibition of IGF-IR synthesis [332].  
 
Clinical findings 
Loss of PTEN protein was reported to correlate with pathological markers of poor 
prognosis in prostate cancer [333]. A relative reciprocity of mutations in PTEN and NRAS 
was also reported in melanoma, suggesting that the two genetic changes, in a subset of 
cutaneous melanomas, are functionally overlapping [334]. In multiple myeloma (MM) it 
was shown that human lines possessing the highest Akt activity lost PTEN expression 
[335]. Sequencing analysis demonstrated that the PTEN gene contains a deletion. 
Restoration of PTEN expression suppressed IGF-I-induced Akt activity, suggesting that 
loss of PTEN is responsible for uncontrolled Akt activity in MM lines [335]. In 
lymphoma/leukemia-derived cell lines, an inverse relationship between PTEN and 
phosphorylated Akt was observed in 63% of cell lines [336]. No cell lines showed 
absence of PTEN expression, whereas 50% of cell lines showed low PTEN expression 
[336]. Another study demonstrated the phosphorylation of Akt is accompanied by the 
loss of PTEN in clinical specimens of endometrial carcinomas [337]. Phosphorylation of 
Akt was accompanied by the loss of PTEN in clinical specimens of endometrial cancers 
[338]. The survival rate for PTEN-positive patients was significantly higher than that for 
PTEN-negative or -heterogeneous staining patients, and thus PTEN-positive staining was 
proposed to be a significant prognostic indicator of favorable survival for patients with 
advanced endometrial cancer [338]. In glioma, a strong inverse correlation was described 
between PTEN levels and both phosphorylated Akt expression and Akt activity [339]. A 
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significant association was evident between PTEN expression level and histology. PTEN 
levels were highest in normal brain, lowest in GBM tumors, and intermediate in grade II 
oligoastrocytomas [339]. Another study demonstrated that loss PTEN was highly 
correlated with activation of the main PI3K effector Akt in vivo [340]. It was also shown 
that Akt activation is significantly correlated with mTOR, the family of forkhead 
transcription factors (FOXO1, FOXO3a, and FOXO4) and the S6 protein [340]. 
Expression of the mutant EGFRvIII was also tightly correlated with phosphorylation of 
these effectors, demonstrating an additional route to PI3K pathway activation in 
glioblastomas in vivo [340]. PTEN expression correlated significantly with survival time 
within the entire cohort and was associated with survival within the subgroup of GBM 
tumors [339]. Thus, reduced PTEN expression is ubiquitous among GBM tumors and 
may play a role in the development of low-grade gliomas. PTEN inactivation in gliomas 
portends a particularly aggressive clinical behavior [339]. 
 
Therapeutic implications 
It was shown that transformed cells of PTEN (+/-) mice have elevated levels of 
phosphorylated Akt and activated p70(S6K) associated with an increase in proliferation. 
Pharmacological inactivation of mTOR/RAFT/FRAP reduced neoplastic proliferation, 
tumor size, and p70(S6K) activity, but did not affect the status of Akt [341]. These data 
suggesed that p70(S6K) and possibly other targets of mTOR contribute significantly to 
tumor development and that inhibition of these proteins may be therapeutic for cancer 
patients with deranged PI3K signaling [341]. In vitro and in vivo studies of isogenic 
PTEN(+/+) and PTEN(-/-) mouse cells as well as human cancer cells with defined PTEN 
status confirmed that the growth of PTEN null cells was blocked preferentially by 
pharmacologic FRAP/mTOR inhibition [342]. Enhanced tumor growth caused by 
constitutive activation of Akt in PTEN (+/+) cells also was reversed by CCI-779 
(rapamycin derivative) treatment, indicating that mTOR functions downstream of Akt in 
tumorigenesis [342]. Loss of PTEN correlated with increased S6 kinase activity and 
phosphorylation of ribosomal S6 protein, providing evidence for activation of the 
FRAP/mTOR pathway in these cells [342]. Another study aimed to determine the effects 
of PTEN status and treatment with rapamycin in the response of prostate cancer cell lines 
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to doxorubicin [343]. The PTEN-positive cells were significantly more susceptible to the 
anti-proliferative effects of doxorubicin as compared with the PTEN-negative cells. 
Transfection of PTEN into the PTEN-negative decreased the activation of Akt and the 
downstream p70(S6K) and reversed the resistance to doxorubicin in these cells, 
indicating that changes in PTEN status/Akt activation modulate the cellular response to 
doxorubicin [343]. Treatment of PC-3 PTEN-negative cells with rapamycin inhibited 
p70(S6K) and increased the proliferative response of these cells to doxorubicin [343]. 
Furthermore, treatment of mice bearing the PTEN-negative prostate cancer xenografts 
with CCI-779, an ester of rapamycin combined with doxorubicin, inhibited the growth of 
the doxorubicin-resistant tumors confirming the observations in vitro [343]. Thus, 
rapamycin and CCI-779, by interacting with downstream intermediates in the PI3K/Akt 
signaling pathway, reverse the resistance to doxorubicin conferred by PTEN 
mutation/Akt activation [343]. Another study examined the possible mechanisms of 
resistance to the EGFR inhibitor ZD1839 (Iressa) in tumor cells with variable levels of 
EGFR [344]. The results suggested that loss of PTEN, by permitting a high level of Akt 
activity independent of RTK inputs, can temporally dissociate the inhibition of the EGFR 
with that of Akt induced by EGFR inhibitors [344]. Thus, it was suggested that in EGFR-
expressing tumor cells with concomitant amplification(s) of PI3K/Akt signaling, 
combined blockade of the EGFR tyrosine kinase and Akt should be considered as a 
therapeutic approach [344].In another study, sensitivity to ZD1839 required intact growth 
factor receptor-stimulated Akt signaling activity. PTEN loss leads to uncoupling of this 
signaling pathway and results in ZD1839 resistance, which could be reversed with 
reintroduction of PTEN or pharmacologic down-regulation of constitutive PI3K/Akt 
pathway activity [345]. 
 In myeloma, PI3K inhibitors preferentially suppressed PTEN-null myeloma 
growth to those expressing PTEN, indicating that PI3K activation is more critical for 
growth and survival of those lines with PTEN mutations than others expressing a 
functional PTEN gene [346]. Expression of an active Akt, reversed wortmannin- and 
dexamethasone-induced apoptosis and growth inhibition in PTEN-null myeloma lines, 
suggesting that Akt lies downstream of PI3K for PTEN-null myeloma survival and 
dexamethasone resistance [346]. 
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The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable 
therapeutic efficacy in certain patients with ErbB2-overexpressing tumors. The overall 
trastuzumab response rate for reasons that ae not completely understood. It was reported 
that PTEN activation contributes to trastuzumab's antitumor activity. Reducing PTEN in 
breast cancer cells by antisense oligonucleotides conferred trastuzumab resistance in vitro 
and in vivo[347]. Patients with PTEN-deficient breast cancers had significantly poorer 
responses to trastuzumab-based therapy than those with normal PTEN [347]. 
Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance [347]. 
Thus, PTEN deficiency was proposed to be a predictor for trastuzumab resistance [347].  
Forkhead family of transcription factors (FOXO1a, FOXO3a, FOXO4) are 
downstream targets of the PI3K/PTEN/Akt pathway. In PTEN null cells, FOXO1a is 
inactivated by PI3K-dependent phosphorylation and mislocalization to the cytoplasm, yet 
still undergoes nucleocytoplasmic shuttling. Since forcible localization of FOXO1a to the 
nucleus can reverse tumorigenicity of PTEN null cells, a high-content, chemical genetic 
screen for inhibitors of FOXO1a nuclear export was performed [348]. The compounds 
detected in the primary screen were retested in secondary assays, and structure-function 
relationships were identified. Novel general export inhibitors were found that react with 
CRM1 as well as a number of compounds that inhibit PI3K/Akt signaling, among which 
are included multiple antagonists of calmodulin signaling [348]. 
 
Interactions with other tumor suppressor pathways 
The PTEN tumor suppressor protein inhibits PI3K/Akt signaling that promotes 
translocation of Mdm2 into the nucleus [229, 349]. When restricted to the cytoplasm, 
Mdm2 is degraded [349]. The ability of PTEN to inhibit the nuclear entry of Mdm2 
increases the cellular content and transactivation of the p53 tumor suppressor protein. 
Retroviral transduction of PTEN into PTEN null glioblastoma cells increases p53 activity 
and expression of p53 target genes and induces cell cycle arrest [350]. U87MG/PTEN 
glioblastoma cells were more sensitive than U87MG/PTEN null cells to death induced by 
etoposide, a chemotherapeutic agent that induces DNA damage [350]. These results 
established a direct connection between the activities of two major tumor suppressors and 
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show that they act together to respond to stresses and malignancies. PTEN protects p53 
from survival signals, permitting p53 to function as a guardian of the genome [349, 350]. 
 
3.3.9.3 The human PIK3CA oncogene 
Increases in PIK3CA copy numbers 
Studies using comparative genomic hybridization (CGH) revealed several regions of 
recurrent, abnormal, DNA sequence copy number that may encode genes involved in the 
genesis or progression of ovarian cancer [351]. One region at 3q26 found to be increased 
in copy number in approximately 40% of ovarian and others cancers contains PIK3CA, 
which encodes the p110α catalytic subunit of PI3K [351]. PIK3CA was shown to be 
frequently increased in copy number in ovarian cancers, and the increased copy number 
is associated with increased PIK3CA transcription, p110α protein expression and PI3K 
activity and the treatment with the PI3K inhibitor LY294002 decreased proliferation and 
increases apoptosis [351]. These observations suggested PIK3CA is an oncogene that has 
an important role in ovarian cancer [351]. In a subsequent study, PIK3CA mRNA was 
detected in 66.6% of stage I and 93.9% of advanced stage ovarian cancer specimens and 
in all ovarian cancer cell lines [352]. PIK3CA mRNA levels were significantly higher in 
invasive carcinomas compared with benign and low malignant potential neoplasms [352]. 
Strong expression of immunoreactive p110α was detected in tumor cells and/or stroma 
endothelium [352]. PIK3CA expression in vivo positively correlated, both at the mRNA 
and the protein level, with the expression of VEGF as well as with the extent of 
microvascular development [352]. Furthermore, PIK3CA mRNA over-expression 
positively correlated with increased proliferation and decreased apoptosis of tumor cells 
in vivo [352]. In vitro, PIK3CA expression positively correlated with the expression of 
VEGF in ovarian cancer cells, whereas LY294002 reduced both the constitutive and 
inducible expression of HIF-1α at the mRNA and protein levels and abrogated VEGF up-
regulation by glucose starvation [352]. Furthermore, LY294002 suppressed cell 
proliferation and, at higher doses, induced marked apoptosis in ovarian cancer cells. 
Collectively, these data strongly indicate that PIK3CA supports ovarian cancer growth 
through multiple and independent pathways affecting cell proliferation, apoptosis and 
angiogenesis, and plays an important role in ovarian cancer progression [352]. 
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The results of CGH also showed that the 3q26.3 amplification was the most 
consistent chromosomal aberration in primary tissues of cervical carcinoma, and a 
positive correlation between an increased copy number of PIK3CA and 3q26.3 
amplification was found in tumor tissues and in cervical cancer cell lines [353]. In 
cervical cancer cell lines harboring amplified PIK3CA, the expression of p110α was 
increased, and was subsequently associated with high kinase activity [353]. These 
evidences supported that PIK3CA is an oncogene in cervical cancer and PIK3CA 
amplification may be linked to cervical tumorigenesis [353]. In low-grade head and neck 
squamous cell carcinomas PIK3CA was over-represented, as analyzed by CGH or 
fluorescence in situ hybridization [354]. These results indicated that PIK3CA may 
participate to the progression of head and neck tumors [354]. 
In another study, PIK3CA was identified as an oncogene involved in squamous 
cell carcinomas [355]. Simultaneous abnormalities in both pathways were rare in primary 
tumors, suggesting that amplification of PIK3CA and mutation of p53 are mutually 
exclusive events and either event is able to promote a malignant phenotype [355]. 
Moreover, the negative effect of p53 induction on cell survival involved the 
transcriptional inhibition of PIK3CA that was independent of PTEN activity, as PTEN 
was not expressed in the primary tumors [355]. Conversely, constitutive activation of 
PIK3CA resulted in resistance to p53-related apoptosis in PTEN deficient cells [355]. 
Thus, p53 regulates cell survival by inhibiting the PI3K/AKT prosurvival signal 
independent of PTEN in epithelial tumors. This inhibition is required for p53-mediated 
apoptosis in malignant cells [355]. 
Array CGH was used to identify genomic abnormalities at loci encoding genes 
that may contribute to lung cancer transformation and progression in squamous 
carcinomas (SqCas) and adenocarcinomas (AdCas) [356]. The most noticeable 
differences between SqCas and AdCas were gain of chromosome 3q22-q26 and loss of 
chromosome 3p [356]. These occurred almost exclusively in SqCas and the region of 
recurrent increase contained PIK3CA [356]. The activity of Akt was higher in SqCas than 
in AdCas and was correlated with PIK3CA copy number, suggesting that these copy 
number increases contribute to activation of PI3K signaling in SqCas of the lung [356]. 
In head and neck squamous cell carcinoma (HNSCC) a study suggested that 3q26 copy 
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number gain and amplification represent early genomic aberrations in HNSCC 
carcinogenesis [357]. In addition, p110α mRNA and protein expression in HNSCC may 
be regulated by these genomic aberrations as well as by epigenetic events [357]. 
 
Discovery of somatic mutations in PIK3CA 
To determine if PI3Ks are genetically altered in tumorigenesis, the PI3K genes were 
sequenced in human cancers and corresponding normal tissue [358]. Eight PI3K and eight 
PI3K-like genes, including two uncharacterized genes, were identified in the human 
genome [358]. The sequences of 117 exons that encode the predicted kinase domains of 
these genes were examined in 35 colorectal cancers [358]. PIK3CA was the only gene 
with somatic (i.e., tumor-specific) mutations [358]. Subsequent sequence analysis of all 
coding exons of PIK3CA in 199 additional colorectal cancers revealed mutations in a total 
of 74 tumors (32%). The authors also evaluated 76 premalignant colorectal tumors and 
found only two mutations [358]. Thus, PIK3CA mutations generally arise late in 
tumorigenesis, just before or coincident with invasion. Mutations in PIK3CA were also 
identified in glioblastoma, gastric cancer, breast cancer and lung cancer [358]. In total, 92 
mutations were observed, all of which were determined to be somatic in the cancers that 
could be assessed [358]. No truncating mutations were observed and >75% of alterations 
occurred in two small clusters in the helical and kinase domains [358]. The affected 
residues within these clusters are highly conserved evolutionarily. The lipid kinase 
activity of wild-type p110α or a "hot-spot" mutants (H1047R) were measured. 
Expression of mutant p110α conferred more lipid kinase activity than expression of wild-
type protein [358]. These data suggested that mutant PIK3CA was likely to function as an 
oncogene in human cancers [358, 359]. This idea is consistent with previously reported 
alterations of members of the PI3K pathway, particularly inactivation of the PTEN tumor 
suppressor [359]. This study found no evidence of PIK3CA gene amplification in 96 
colorectal cancers, suggesting that amplification is not a common mechanism of 
activation in this tumor type [358]. A subsequent study analysed 340 genes coding for 
serine/threonine kinases in colorectal tumours [360]. A total of 23 changes, including a 
majority (20) of non-synonymous point mutations were identified [360]. The gene 
mutations affected eight different proteins, including PDK1 (3 mutations out of which 
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two mutations affected the same residue in the kinase domain) and Akt2 (2 mutations) 
[360]. Eighteen of the 23 somatic mutations occurred at evolutionarily conserved residues 
in the genes encoding the serine/threonine kinases [360].  
 
 
Clinical findings related to PIK3CA mutations 
A subsequent report showed that 25% of breast cancers contain somatic mutations in 
PIK3CA, with the majority of mutations located in the kinase domain [358]. These results 
demonstrate that PIK3CA is the most mutated oncogene in breast cancer and support a 
role for PIK3CA in epithelial carcinogenesis [358]. A large-scale mutational analysis of 
the helical and catalytic domains of PIK3CA was performed in brain tumors [361]. A 
total of 13 mutations of PIK3CA within these specific domains were identified in 
anaplastic oligodendrogliomas, anaplastic astrocytomas, glioblastoma multiforme, and 
medulloblastomas, whereas no mutations were identified in ependymomas or low-grade 
astrocytomas [361]. These observations implicated PIK3CA as an oncogene in a wider 
spectrum of adult and pediatric brain tumors and suggested that PIK3CA may be a useful 
diagnostic marker or a therapeutic target in these cancers [361]. 
Another group screened a large panel of primary human tumors for mutations in 
all coding exons of PIK3CA [362]. A strong proportion of primary breast cancers (40%) 
harbored mutations in PIK3CA [362]. Mutations were not associated with histologic 
subtype, estrogen receptor status, grade or presence of tumor in lymph nodes [362]. 
Among the primary epithelial ovarian cancers only 6.6% contain somatic mutations, but 
there was a clear histologic subtype bias in their distribution [362]. Only a minority 
(2.3%) of serous carcinomas had PIK3CA mutations compared with 20.0% of 
endometrioid and clear cell cancers. In contrast, PIK3CA gene amplification (>7-fold) 
was common among all histologic subtypes and was inversely associated with the 
presence of mutations [362]. Overall, PIK3CA mutation or gene amplification was 
detected in 30.5% of all ovarian cancers and 45% of the endometrioid and clear cell 
subtypes [362]. In advanced ovarian carcinomas, activating PIK3CA missense mutations 
were found in only about 4% of the cases [363]. Somatic missense mutations in PIK3CA 
were observed in 12% of ovarian carcinomas, and in 18% breast carcinomas in [364]. 
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Another study reported PIK3CA somatic mutations in hepatocellular carcinomas (35.6%), 
breast carcinomas (26.9%), gastric carcinomas (6.5%), acute leukemias (1.1%) and non-
small-cell lung cancers (1.3%) [365]. Some of the PIK3CA mutations were detected in 
the early lesions of breast cancer carcinoma, hepatocellular carcinoma, and gastric 
carcinomas, suggesting that PIK3CA mutation may occur independent of stage of the 
tumors [365]. PIK3CA mutations were identified in 26% of human breast tumor samples 
and cell lines at about equal frequency in tumor stages I to IV in another study [366]. A 
highly significant association between PIK3CA mutations and retention of PTEN protein 
expression was observed. In addition, PIK3CA mutations were associated with expression 
of estrogen and progesterone receptors, lymph node metastasis, and ErbB2 
overexpression. The fact that PIK3CA mutations and PTEN loss were nearly mutually 
exclusive implied that deregulated PI3K signaling is critical for tumorigenesis in breast 
cancers and that loss of either PIK3CA or PTEN abrogates the selective pressure for 
targeting of the other gene. However, a subsequent study found that PIK3CA and PTEN 
mutations in breat cancer were not mutually exclusive and correlated with similar 
prognostic factors [367]. Intriguingly, PIK3CA mutations predicted for longer local 
recurrence-free survival [367]. In thyroid cancer, non-synonymous somatic mutations in 
PIK3CA were found in anaplastic thyroid carcinomas (23%) [368]. In endometrial 
carcinoma, PIK3CA mutations occurred at high frequency (36%) as did the coexistence 
of PIK3CA/PTEN mutations (26%) [369]. PIK3CA mutations were more common in 
tumors with PTEN mutations (46%) compared with those without PTEN mutations (24%) 
[369]. In head and neck squamous cell carcinoma, mutations in PIK3CA were reported in 
11% of the cases analysed [370]. Three of the four mutations (H1047R, E542K, E545K) 
had been previously reported as hotspot mutations [370]. In pancreatic cancer a recent 
study described PIK3CA mutations in a fraction (11%) of the specimens analysed and 
some of the somatic mutations were novel [371].  
 
Validation of PIK3CA as an oncogene 
The oncogenic potential of three of the most commonly observed PIK3CA mutations 
(E542K, E545K, H1047R) was investigated in chicken embryo fibroblasts [372]. All 
three mutants induced oncogenic transformation with high efficiency [372]. The mutant-
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transformed cells displayed constitutive phosphorylation of Akt, of p70(S6K), and of the 
4E-BP1 [372]. Rapamycin strongly suppressed cellular transformation induced by the 
PI3K mutants, suggesting that TOR and its downstream targets are essential components 
of the transformation process [372]. It was also shown that three prevalent mutants of 
p110α are oncogenic in vivo [373]. The mutants induced tumors in the chorioallantoic 
membrane of the chicken embryo and cause hemangiosarcomas in the animal [373]. 
These tumors were marked by increased angiogenesis and an activation of the Akt 
pathway [373]. The TOR inhibitor RAD001 blocked tumor growth induced by the 
H1047R p110α mutant [373]. In a subsequent study, all of eight PIK3CA mutations 
examined were shown increased p110α lipid kinase activity compared with the wild-type 
enzyme [374]. All the mutants strongly activated Akt and p70(S6K) and also induced 
morphologic changes, loss of contact inhibition, and anchorage-independent growth of 
NIH3T3 cells [374]. The hotspot mutations E542K, E545K, and H1047R, all had high 
enzymatic and transforming activities [374]. These results showed that almost all the 
colon cancer-associated PIK3CA mutations are functionally active so that they are likely 
to be involved in carcinogenesis [374]. In a recent report, a panel of rare PIK3CA mutants 
was evalulated in chicken fibroblast tansformation assays, which also revealed their 
oncogenic potential and mechanism of activation [375]. 
To evaluate the consequences of PIK3CA alterations, the two most common 
mutations were inactivated by gene targeting in colorectal cancer cells [376]. 
Biochemical analyses of these cells showed that mutant PIK3CA selectively regulated the 
phosphorylation of Akt and of forkhead transcription factors [376]. PIK3CA mutations 
had little effect on growth under standard conditions, but reduced cellular dependence on 
growth factors [376]. PIK3CA mutations resulted in attenuation of apoptosis and 
facilitated tumor invasion [376]. Importantly, treatment with LY294002 abrogated 
PIK3CA signaling and preferentially inhibited growth of PIK3CA mutant cells [376]. A 
recent study also showed that PIK3CA mutant colon cancer cell lines have increased 
metastatic potential in an orthotopic model [377]. Two PIK3CA mutants observed in 
breast cancer (E545K and H1047R) were also tested in the MCF-10A immortalized 
breast epithelial cell line [378]. Both variants displayed higher PI3K activity than wild-
type p110α yet remained sensitive to pharmacologic PI3K inhibition [378]. In addition, 
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expression of p110α mutants in mammary epithelial cells induced multiple phenotypic 
alterations characteristic of breast tumor cells, including anchorage-independent 
proliferation in soft agar, growth factor-independent proliferation, and protection from 
anoikis [378]. Expression of these mutant p110α isoforms also confered increased 
resistance to paclitaxel and induced abnormal mammary acinar morphogenesis in three-
dimensional basement membrane cultures [378]. 
Another study compared the biochemical activity and transforming potential of 
mutant forms of p110α and p110β in a human mammary epithelial cell system [379]. The 
two most common tumor-derived alleles of p110α (H1047R and E545K) potently 
activated PI3K signaling [379]. Human mammary epithelial cells expressing these alleles 
grew efficiently in soft agar and as orthotopic tumors in nude mice [379]. A mutation in 
p110β homologous to the E545K allele of p110α was then constructed, but the resulting 
p110β mutant was only weakly activated and induced minimal soft-agar growth [379]. 
However, a gene fusion of p110β with a membrane anchor was highly active and 
transforming in both soft-agar and orthotopic nude mouse assays [379]. Work by another 
group investigated the oncogenic potential of all 4 catalytic class I PI3K isoforms [380]. 
At physiological levels of expression, the wild-type p110α isoform lacked oncogenic 
potential, but gain-of-function mutations and overexpression of p110α were correlated 
with oncogenicity [380]. The p110β, p110γ and p110δ isoforms induced transformation 
of cultured cells as wild-type proteins, which could be suppressed by rapamycin [380]. 
The p110δ isoform constitutively activated the Akt signaling pathway, but p110γ 
activated Akt only in the presence of serum [380]. The p110 isoforms also differed in 
their requirements for upstream (Ras) signaling [380].  
 
3.4 Lung cancer 
Lung cancer is the main cause of neoplastic death in the world and accounts for 
approximately 26% of all cancer deaths.  Lung cancer causes the death of 85% of newly 
diagnosed patients within five years [381, 382]. Worldwide over 1 million people die 
annually in consequence of lung cancer [383]. Approximately 85 % of these cases are 
non-small cell lung cancer (NSCLC) with the rest being small-cell lung cancer (SCLC) 
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[384]. NSCLC is composed of three main types: squamous cell carcinoma, 
adenocarcinoma, and large cell carcinoma. The development of lung cancer is associated 
with tobacco smoking and exposure to asbestos, radon and other potential carcinogens. 
Current treatments of lung cancer include surgery, radiotherapy and chemotherapy. 
Chemotherapy improves the survival rate of NSCLC patients although the median 5-year 
survival rate is still only 15% [385]. SCLC is correlated with tobacco smoking in 98% of 
cases and patients have a very poor outcome with a 5-year survival of less than 5% [386].  
In the past years, the molecular mechanisms responsible for cancer development 
have been extensively studied and the contribution of abnormal Ras and PI3K signaling 
to tumor growth, maintenance and chemoresistance has been well documented [387]. A 
growing body of evidence suggests that lung tumors selectively up-regulate different 
signaling pathways implicated in cell proliferation, survival and angiogenesis, in order to 
become invasive and chemoresistant [388]. It has also become clear that deregulated 
RTKs and their downstream effectors possess a high oncogenic capacity. Recently, an 
interesting model termed “oncogene addiction” has been proposed for tumors which 
develop a dependency on a single oncogenic signaling pathway and there is growing 
experimental evidence that this mechanism is indeed very important for tumor cell 
survival [389, 390]. Even if unexpected in its theoretical simplicity, the specific targeting 
of activated oncoproteins can lead to tumor growth arrest and cause apoptosis [390]. One 
of the most prominent examples so far is the successful treatment of chronic 
myelogenous leukemia (CML) patients with imatinib (Gleevec) an inhibitor of Bcr-Abl 
[391]. A beneficial response to imatinib has also been reported in gastrointestinal stromal 
tumors (GISTs) patient with mutationally activated c-Kit [392]. Moreover, the improved 
outcome of NSCLC patients with mutationally activated or amplified EGFR in response 
to treatment with either gefitinib or erlotinib [393-395], further supports this model.  
The PI3K/Akt/mTOR pathway and its implication in human cancer have been 
extensively reviewed in the past years [387, 396, 397]. mTOR is a serine/threonine kinase 
which has emerged in the past 5 years as one of the most important intracellular signaling 
enzyme regulating cell growth, survival and motility in cancer cells [398].  mTOR has 
been identified as a downstream target of both the PI3K [399, 400] and Ras [401-404] 
signaling pathways. The discovery of the highly specific and potent mTOR inhibitor 
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rapamycin and its derivatives (RAD001, CCI-779, and AP23573) further boosted the 
interest of the scientific community in elucidating its biological function [405, 406]. 
Below, we will summarize the current knowledge about the contribution and implication 
of the PI3K/Akt/mTOR pathway in lung cancer development and maintenance. 
 
3.4.1 Non-small cell lung cancer (NSCLC) 
Many lines of evidence point to the importance of deregulated PI3K/Akt/mTOR 
signaling in lung cancer. The PI3K/Akt pathway was reported to mediate the effects of 
several tyrosine kinase receptors on proliferation and survival in small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC) [388]. These receptors include c-Met 
[407, 408], EGFR [409, 410], c-Kit [137] and IGF-IR [411]. Over-expression of both the 
regulatory p85α and the catalytic p110α subunits of PI3K was reported in primary human 
lung carcinomas [12]. Genomic amplification of the PIK3CA gene was also documented 
in several lung cancers and in pre-invasive bronchial lesions, suggesting an implication of 
the PI3K pathway in lung cancer development [412]. The up-regulations of PI3K may be 
linked to tumor-cell transformation in lung cancer. Most lung tumors also demonstrate 
activation of downstream mediators of PI3K such as Akt or mTOR. Several groups have 
reported that Akt can be activated by amplification or mutations of upstream components 
in the PI3K pathway. Notably, mutated EGFR has been reported to have higher 
expression levels compared to the wild type protein and furthermore to induce a higher 
activation of Akt and signal transducer and activator of transcription (STAT), but not of 
the Erk signaling pathway [393, 409, 413]. Akt activation can also occur through direct 
over-expression or activation of the Akt protein itself. Brognard et al. reported PI3K-
dependent Akt phosphorylation in a panel of NSCLC cell lines, which was correlated 
with resistance to chemotherapy. The PI3K inhibitor LY294002 alone or in combination 
with chemotherapy treatment rendered NSCLC cell lines with highly activated Akt more 
responsive to apoptosis and growth inhibition [287, 407]. Increased phosphorylation of 
Akt was also reported in pre-malignant and malignant human bronchial epithelial cells, 
but not in normal bronchial cells [414]. Moreover, the ability of a novel pro-apoptotic 
drug to induce apoptosis in these cells correlated with increased Akt activation levels 
[414]. Furthermore, immunohistochemical analysis detected high levels of 
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phosphorylated Akt in tumor tissues from NSCLC patients and revealed the implication 
of activated PI3K/Akt pathway in disease progression [412, 415-417]. Activation of Akt 
was also observed in primary NSCLC tumors, supporting a role of activated Akt in the 
conversion of a precursor lung lesion to malignant cancer [415, 416, 418]. Moreover, 
phosphorylation or over-expression of Akt correlated with poor prognosis in NSCLC 
patients with stage I disease or with primary tumors [417, 419]. Another study identified 
somatic mutations in the Akt gene, which could contribute to oncogenesis in a subset of 
lung carcinomas [420]. It has also been shown that the over-expression of PI3K or Akt 
was frequently associated with low expression of PTEN in NSCLC [421-424]. The tumor 
suppressor gene PTEN negatively regulates the PI3K/Akt pathway and cancer cells in 
which the PTEN gene is deleted or its expression down-regulated display constitutively 
activated PI3K signaling, which can contribute to lung carcinogenesis [425, 426].  
Concerning mTOR, it was shown that this protein is phosphorylated in several 
lung cancer cell lines [418, 427]. Importantly, mTOR activation was more frequent in 
tumors with gene alterations such as EGFR mutations or PI3K/Akt over-expression 
[428]. Additionally, expression of transgenic K-RasV12 in mice induced the 
transformation of normal alveolar epithelial cells, which was dependent on mTOR 
signaling [429]. Indeed, mTOR phosphorylation increased with the malignant 
progression and blocking mTOR with the rapamycin derivative CCI-779 was sufficient to 
block lung tumor progression [429]. Recently, mTOR has been implicated in the 
development of metastasis in NSCLC. Phillips et al. reported that the metastatic potential 
of NSCLC cells is increased under conditions of low oxygen tension and chemokine 
receptor CXCR4 and EGFR overexpression, and that this process could be blocked by 
rapamycin [430]. Furthermore, the simultaneous inhibition of the PI3K/Akt and c-Jun 
NH2-terminal kinase (JNK) pathways has been demonstrated to increase apoptosis in 
NSCLC, both in vitro and in vivo [431]. Moreover, over-expression of a dominant-
negative mutant of the regulatory PI3K p85α subunit induced apoptosis in NSCLC cells 
[432]. The same effect was observed after inhibition of Akt by expression of a dominant-
negative mutant of this protein in NSCLC cell lines [287].  
Nicotine, which is an important component of cigarette smoke, was shown to activate 
growth-promoting pathways, particularly the PI3K/Akt/mTOR pathway [433, 434] and 
 58
was associated with NF-κB-dependent resistance to chemotherapeutic drugs [433]. This 
activation was accompanied with endogenous acetylcholine release, which may serve as 
an autocrine or paracrine growth factor and may promote the development of lung cancer 
[433, 434]. The inhibition of PI3K or Akt blocked lung cancer cells growth triggered by 
nicotine, suggesting that the activation of the PI3K/Akt pathway is involved in nicotine-
induced cell survival [435, 436]. Furthermore, it has been found that BAD is inactivated 
as a result of activation of the PI3K/Akt pathway in response to nicotine exposure, thus 
leading to a cell growth advantage. Nicotine-dependent Akt activation also effectively led 
to increased phosphorylation of Bax, another member of the Bcl-2 protein family and 
thus abrogated its pro-apoptotic function [435]. The correlation between cigarette 
smoking and NSCLC development has been further supported by the findings that 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen, 
activates both the Erk and Akt signaling pathways in association with increased survival 
of normal non-immortalized lung epithelial cells [437].   
In addition, activation of the PI3K pathway has been shown to increase resistance 
to chemo- or radiotherapy [287]. Indeed, NSCLC cells resistant to gefitinib demonstrated 
increased PI3K/Akt activation [422, 438]. The inhibition of PI3K led to sensitization of 
lung cancer cells to radiotherapy [439], or chemotherapy [411]. Accordingly, RAD001 
(Everolimus) sensitized NSCLC cells to the DNA-damaging agent cisplatin by 
downregulation of p21, which is required for DNA repair [440]. Based on these data, 
inhibition of the PI3K/AKT/mTOR pathway has been widely proposed to represent a 
promising therapeutic approach for lung cancer. Taken together, these data also indicate 
that the activation of PI3K/Akt/mTOR pathway plays a significant role in the 
development, growth and chemoresistance in NSCLC.  
 
3.4.2 Small cell lung cancer (SCLC) 
Small cell lung cancer (SCLC) represents 10-15% of all lung cancer cases and is strongly 
associated with tobacco smoking. This type of lung cancer is initially very sensitive to 
chemotherapy and radiotherapy. However, the initial therapeutic responsiveness is 
followed by disease recurrence and therefore the outcome is still very poor [386, 441]. 
Although the understanding of the biology of this cancer has greatly increased in the past 
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20 years, no obvious survival improvement has been achieved in the clinic so far. A 
plethora of genetic and molecular alterations have been reported, including autocrine 
signaling loops, oncogene activation and loss of tumor-suppressor genes [384]. 
Constitutive activation of the PI3K/Akt/mTOR pathway was related to the transformed 
phenotype in SCLC cells in the late 1990s [286]. Differential over-expression for several 
PI3K isoforms and their contribution to Akt activation were demonstrated in a panel of 
SCLC cell lines [137]. Moreover, several autocrine loops have been described in SCLC 
cells, including SCF/c-Kit, IGF-I/IGF-IR and hepatocyte growth factor (HGF)/c-Met. 
Inhibition of the PI3K/Akt pathway was able to reverse the mitogenic effects of these 
autocrine loops [411]. In addition, immunohistochemical analysis detected high levels 
(70%) of phosphorylated Akt in tumor tissues from SCLC patients and revealed the 
implication of the activated pathway in disease progression [412, 442]. This observation 
is difficult to explain solely through mutations in the PTEN gene, since this event has 
been found only in 15% of SCLC tumors [443-445]. Moreover, the PI3K pathway was 
also shown to be activated through integrins in response to adhesion on extracellular 
matrix (ECM) molecules and this resulted in resistance of SCLC cells to various 
therapies and protection from apoptosis [446, 447].  
Further studies have shown that inhibition of the PI3K/Akt/mTOR pathway with 
LY294002 or rapamycin led to apoptosis and decreased cell growth in SCLC cells [446]. 
The same effect was observed after inhibition of Akt by expression of a dominant-
negative mutant of this protein in SCLC cells [411]. Adherent-growing SCLC cells, 
which are those thought to initially survive chemotherapy, have been reported to activate 
Akt and thus to increase chemo- and radiotherapy resistance by mechanisms involving 
over-expression of anti-apoptotic proteins [448]. One possible mechanism by which 
SCLC cells can escape the effects of cytotoxic drugs was discovered in experiments 
elucidating SCLC responses to cisplatin, a DNA-damaging agent. Surprisingly, treatment 
with cisplatin up-regulated Akt activation and contributed to the expression of pro-
survival proteins in SCLC cells [449].  Additionally, it has been found that a rapamycin 
derivative (CCI-779) sensitized cisplatin-resistant SCLC cells to the effects of the 
cytotoxic drug [450]. Unfortunately CCI-779 did not improve patient survival, when 
administrated as a single agent in a Phase II clinical trial for SCLC patients after 
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chemotherapy induction [451]. Collectively, these data demonstrate a significant role for 
the PI3K/Akt/mTOR pathway in the biology of SCLC. However, the first line targeted 
therapy was disappointing in the clinic. Very recent pre-clinical studies with vascular 
endothelial growth factor receptor (VEGFR) inhibitors and other multi-targeted drugs 
showed promising result [452-454] and further multi-targeted clinical trials are expected 
with interest.   
For SCLC, there exist so far no pre-clinical studies investigating the potential 
therapeutical benefit of the use of rapamycin derivatives in combination with 
chemotherapy or other targeted inhibitors. Pandya et al. reported the failure of CCI-779 
to improve SCLC patient survival in a Phase II clinical trial [451]. This disappointing 
result should first lead to studies aimed at gaining a better understanding of the molecular 
deregulations in the PI3K/Akt/mTOR axis in SCLC. Based on established findings it will 
then be possible to choose the optimal therapeutic strategy for selected patient groups, 
which are more likely to benefit from targeted treatment. In fact, CCI-779 showed 
activity in Phase II clinical trials in patients with renal cell carcinoma and glioblastoma 
[455-457]. However, it has been found that a small population of glioblastoma patients 
with highly elevated phospho-S6K levels mainly benefited from CCI-779 treatment 
[456]. Interestingly, elevated protein expression and phosphorylation of S6K1 and its 
recently identified homologue S6K2 have been reported in different SCLC cell lines, as 
compared to normal pneumocytes  [286, 458]. Surprisingly, S6K2 was activated in a 
PI3K-independent manner upon fibroblast growth factor-2 (FGF-2) stimulation. S6K2 
activity could be blocked by a mitogen-activated Erk kinase (MEK) inhibitor and only 
high concentrations of rapamycin were able to partially inhibit its activity [458]. Recent 
studies have elucidated the molecular signaling pathway involving S6K2 and provide a 
possible explanation why rapamycin or its analogues fail to show any anti-tumor activity 
in SCLC patient, when administered as a single agent. Pardo et al. described a novel 
multi-protein complex comprising protein kinase Cε (PKCε), B-Raf and S6K2. FGF-2-
dependent S6K2 activation or a constitutively active mutant of S6K2 were sufficient to 
elevate the expression of anti-apoptotic proteins and render SCLC cells resistant to 
chemotherapy [459]. Furthermore, the authors found that elevated S6K2 protein levels in 
SCLC and NSCLC tumor specimens correlated with chemoresistance. Thus, S6K2 
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represents a novel target, decoupled from mTOR signaling which can promote pro-
survival signaling in SCLC tumors. In this context, increased FGF-2 serum levels were 
correlated with poor survival and active angiogenesis in SCLC patients [460]. 
Furthermore, it has been found that FGF-2 renders SCLC cells more resistant to 
etoposide-induced apoptosis by up-regulation of pro-survival pathways [461, 462]. In 
pre-clinical studies the multitargeted inhibitor SU6668, known to bind and inactivate the 
fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor 
(VEGFR), and platelet-derived growth factor receptor (PDGFR), showed a high efficacy 
in a panel of human tumor xenografts, including lung cancer. High anti-proliferative and 
anti-angiogenic activity has been reported for this compound [463]. The inhibitory effect 
was found to be mainly restricted to vascular endothelial cells in the tumor bed and 
inhibition of their pro-angiogenic capacity [464]. These findings are of particular interest 
for SCLC. Recently, a high vascularization status of SCLC tumors has been reported 
[465]. Furthermore, high levels of VEGF found in SCLC patient plasma were related to 
poor prognosis [466, 467]. Indeed, pre-clinical studies testing antibodies against the 
VEGFR or multi-targeted inhibitors targeting the VEGFR, FGFR and c-Kit have 
described very promising results [452-454, 468, 469]. The molecular events triggering 
angiogenesis require the coordinated cross-talk between VEGF, FGF, PDGF and other 
angiogenic factors, in order to activate endothelial cell proliferation and to facilitate 
neovascularisation. Interestingly, all these growth factors signal through the 
PI3K/Akt/mTOR pathway in cancer cells [470]. Thus, it can be hypothesized that 
effective therapy of SCLC tumors will require combinations of targeted drugs with anti-
angiogenic properties in combination with mTOR inhibitors, in order to inhibit a large 
panel of SCLC molecular dysfunctions and to prevent the development of acquired 
secondary resistance.  
In SCLC, multiple receptor tyrosine kinases are over-expressed and each is 
capable of activating an overlapping spectrum of critical downstream signaling pathways. 
One of these activated downstream signaling events is the Ras pathway. Moreover, Ras 
activation has been shown to be an important mediator of lung carcinogenesis [471, 472]. 
Indeed, mutations or over-expression of Ras, predominantly of the K-Ras isoform, have 
been detected in lung tumours, particularly in adenocarcinoma [473-475]. These 
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mutations were correlated with a shorter survival of patients with NSCLC [476, 477]. In 
contrast, Ras mutations were found in less than 1% of SCLC tumours [478, 479].  
However, despite the lack of known activating mutations of Ras in SCLC, Ras 
proteins are involved in the growth of this cancer. Indeed, our recent work has shown that 
inhibiting Ras signalling potently disrupts proliferation and survival of SCLC cell lines 
and sensitizes SCLC to the effects of chemotherapy [480]. This study showed that the 3-
Hydroxy-3methylglutaryl CoA (HMG-CoA) reductase inhibitor simvastatin inhibits the 
function of Ras proteins and the activation of the MAPK and Akt signalling pathways 
[480]. Simvastatin may represent a potential new drug to inhibit SCLC proliferation. 
Similarly, another drug, gefitinib, has been shown to inhibit the Ras-MAPK pathway in 
three different SCLC cell lines [481]. Thus, targeting Ras pathway might be clinically 
effective against SCLC. 
Additionally, anti-cancer therapies can be directed against regulators of Ras 
activity. Ras-GTPase activating protein (RasGAP) is the main regulator of Ras. It 
controls the conversion of the active form of Ras to inactive Ras-GDP, by accelerating 
GTP hydrolysis. SCLC cell lines express lower levels of RasGAP proteins [482]. This 
altered expression of RasGAP is involved in oncogenesis [483]. It has also been shown 
that RasGAP can be cleaved into an anti-apoptotic fragment [484], which might 
contribute to the highly malignant and terminally therapy-resistant phenotype of SCLC 
[482].  
Moreover, Ras signalling requires the attachment of Ras protein to the plasma 
membrane, a process initiated by the enzyme: farnesyl protein transferase. Farnesyl 
transferase inhibitors (FTIs) specifically prevent farnesylation and have been reported to 
have anti-cancer effects [485]. SCLC cell lines have demonstrated sensitivity to FTIs in 
preclinical studies. Indeed, FTI L-744,832 inhibited the activation of Ras and cell growth 
in three human SCLC cell lines [486]. Unfortunately, this inhibitor demonstrated no 
significant clinical anti-tumour activity as a single agent, in patients with sensitive relapse 
SCLC [487]. Furthermore, the effects of another inhibitor of Ras localization, zoledronic 
acid (ZOL) have been investigated in vitro and in vivo in SCLC [488]. This compound 
prevents both farnesylation and geranylgeranylation of Ras proteins. Geranylgeranylation 
is another modification required by Ras to become functional, especially when farnesyl 
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transferase is inhibited. These properties suggest that ZOL may have stronger anti-cancer 
activity than FTIs. Indeed, ZOL showed an anti-proliferative effect and increased the 
effects of several chemotherapeutic drugs in different SCLC cell lines [488]. It also 
significantly inhibited the growth of SCLC tumours subcutaneously transplanted into 
nude mice [488]. Moreover, it has been reported that ZOL could be a possible 
radiosensitizing agent in SCLC [489], and that it could also be significantly effective for 
treatment of bone metastasis of this cancer [490]. Thus, the use of ZOL may be a 
promising therapeutic strategy and its efficacy should be verified in early phase clinical 
trials. In conclusion, blockade of Ras activation or binding to the plasma membrane may 
represent a promising therapeutic approach for SCLC. 
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4. Overview of the presented publications 
4.1 Arcaro, A., Volinia, S., Zvelebil, M.J., Stein, R., Gout, I., Layton, 
M.J., Ahmadi, K., Watton, S.J., Downward, J. and Waterfield, M.D. (1998). 
Human phosphoinositide 3-kinase C2β, the role of calcium and the C2 
domain in enzyme activity. J. Biol. Chem., 273, 33082-33090 
Impact factor: 5.808; citations: 54 
 
AIM: The aim of the study was the cloning and functional characterization of a novel 
member of the PI3K family of enzymes. 
RESULTS: The cDNA for a human Class II phosphoinositide 3-kinase (PI3KC2β) 
with a C2 domain was cloned from a U937 monocyte cDNA library and the enzyme 
expressed in mammalian and insect cells. Like other Class II PI 3-kinases in vitro, 
PI3KC2β utilizes phosphatidylinositol (PI) and PI 4-monophosphate but not PI 4,5-
biphosphate as substrates in the presence of Mg2+. Remarkably, and unlike other PI3Ks, 
the enzyme can use either Mg-ATP or Ca-ATP to generate PI 3-monophosphate. 
PI3KC2β, like the Class I PI 3-kinases, but unlike PI3KC2α, is sensitive to low 
nanomolar levels of the inhibitor wortmannin. The enzyme is not regulated by the small 
GTP-binding protein Ras. The C2 domain of the enzyme bound anionic phospholipids 
such as PI and phosphatidylserine in vitro, but did not co-operatively bind Ca2+ and 
phospholipids. Deletion of the C2 domain increased the lipid kinase activity suggesting 
that it functions as a negative regulator of the catalytic domain.  
MAIN CONCLUSION: Although presently it is not known whether PI3KC2β is 
regulated by Ca2+ in vivo, our results suggest a novel role for Ca2+ ions in phosphate 
transfer reactions. 
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4.2 Arcaro, A., Zvelebil, M.J., Wallasch, C., Ullrich, A., Waterfield, M.D. 
and Domin, J. (2000). Class II phosphoinositide 3-kinases are downstream 
targets of activated polypeptide growth factor receptors. Mol. Cell. Biol., 20, 
3817-3830 
Impact factor: 6.773; citations: 54 
 
AIM: The aim of this study was to investigate the regulation of the class II PI3K 
enzymes in the context of polypeptide growth factor receptors.  
RESULTS: In this study, we demonstrate that PI3K-C2α and PI3K-C2β represent two 
downstream targets of the activated epidermal growth factor (EGF) receptor in human 
carcinoma-derived A431 cells. Stimulation of quiescent cultures with EGF resulted in the 
rapid recruitment of both enzymes to a phosphotyrosine signaling complex that contained 
the EGF receptor and ErbB2. To examine this interaction in greater detail, PI3KC2β was 
chosen for further investigation. EGF and platelet-derived growth factor also stimulated 
the association of PI3KC2β with their respective receptors in other cells, including 
epithelial cells and fibroblasts. The use of EGF receptor mutants and phosphopeptides 
derived from the EGF receptor and ErbB2 demonstrated that the interaction with 
recombinant PI3K-C2β occurs through E(p)YL/I phosphotyrosine motifs. The N-terminal 
region of PI3KC2β was found to selectively interact with the EGF receptor in vitro, 
suggesting that it mediates the association of this PI3K with the receptor. However, the 
mechanism of this interaction remains unclear.  
MAIN CONCLUSION: We conclude that class II PI3K enzymes may contribute to 
the generation of 3’ phosphoinositides following the activation of polypeptide growth 
factor receptors in vivo and thus mediate certain aspects of their biological activity. 
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4.3 Arcaro, A., Khanzada, U.K., Vanhaesebroeck, B., Tetley, T.D., 
Waterfield, M.D., and Seckl, M.J. (2002). Two distinct phosphoinositide 3-
kinases mediate polypeptide growth factor-stimulated PKB activation. 
EMBO J., 21, 5097-5108 
Impact factor: 10.086; citations: 20 
 
AIM: The aim of this study was to investigate the expression pattern and individual 
functions of class IA and II PI3Ks in human small cell lung cancer (SCLC) cells.  
RESULTS: Here, we show that different human SCLC cell lines over-express distinct 
subsets of class IA and II PI3Ks, which results in striking differences in the signaling 
cascades activated by stem cell factor (SCF). Over-expression of class IA p85/p110α in 
SCLC cells increased SCF-stimulated protein kinase B (PKB) activation and cell growth, 
but did not affect extracellular signal-regulated kinase (Erk) or glycogen synthase kinase-
3 (GSK-3). This effect was selective, since it was not observed in SCLC cell lines over-
expressing p85/p110β or p85/p110δ. The SCF receptor associated with both class IA p85 
and class II PI3KC2β, and both enzymes contributed to SCF-stimulated PKB activity. A 
dominant-negative PI3KC2β blocked both PKB activation and SCLC cell growth in 
response to SCF.  
MAIN CONCLUSION: Together our data provide novel insights into the specificity 
and functional significance of PI3K signaling in human cancer. Both the class IA p110α 
isoform and the class II PI3KC2β play an important role in c-Kit signaling in SCLC cells. 
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4.4 Katso, R.M., Pardo, O.E., Palamidessi, A., Franz, C., Marinov, M., De 
Laurentiis, A., Downward, J., Scita, G., Ridley, A.J., Waterfield, M.D., and 
Arcaro, A. (2006). Phosphoinositide 3-kinase C2β Regulates Cytoskeletal 
Organization and Cell Migration via Rac-dependent Mechanisms. Mol. Biol. 
Cell, 17, 3729-3744 
Impact factor: 6.562; citations: 2 
 
AIM : The aim of this study was to further study the role of PI3KC2β in cytoskeletal 
rearrangements, cell migration and survival in carcinoma cells over-expressing the 
epidermal growth factor receptor (EGFR). 
RESULTS: In this report, we demonstrate that class II phosphoinositide 3-kinase C2β 
(PI3KC2β) associates with the Eps8/Abi1/Sos1 complex and is recruited to the EGF 
receptor as part of a multi-protein signaling complex also involving Shc and Grb2. 
Increased expression of PI3KC2β stimulated Rac activity in A-431 epidermoid 
carcinoma cells, resulting in enhanced membrane ruffling and migration speed of the 
cells. Conversely, expression of dominant negative PI3KC2β reduced Rac activity, 
membrane ruffling, and cell migration. Moreover, PI3KC2β -over-expressing cells were 
protected from anoikis and displayed enhanced proliferation, independently of Rac 
function.  
MAIN CONCLUSION: Taken together, these findings suggest that PI3KC2β 
regulates the migration and survival of human epidermoid carcinoma cells by distinct 
molecular mechanisms. 
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4.5 Khanzada, U.K., Pardo, O.E., Meier, C., Downward, J., Seckl, M.J., 
and Arcaro, A. (2006). Potent inhibition of small cell lung cancer cell 
growth by simvastatin reveals selective functions of Ras isoforms in growth 
factor signalling. Oncogene, 25, 877-887 
Impact factor: 6.582; citations: 11 
 
AIM: The aim of this study was to investigate the impact of the 3-hydroxy-
3methylglutaryl CoA (HMG-CoA) reductase inhibitor simvastatin on human small-cell 
lung cancer (SCLC) cell growth and survival.  
RESULTS: Simvastatin profoundly impaired basal and growth factor-stimulated 
SCLC cell growth in vitro and induced apoptosis. SCLC cells treated with simvastatin 
were sensitized to the effects of the chemotherapeutic agent etoposide. Moreover, SCLC 
tumor growth in vivo was inhibited by simvastatin. These responses correlated with the 
inhibition of stem cell factor (SCF)-stimulated activation of extracellular signal-regulated 
kinase (Erk), protein kinase B (PKB) and ribosomal S6 kinase by simvastatin. 
Constitutive activation of the Erk pathway was sufficient to rescue SCLC cell from the 
effects of simvastatin. The drug did not directly affect activation of c-Kit or its 
localization to lipid rafts, but in addition to its ability to block Ras membrane 
localization, it selectively down-regulated H-Ras protein levels at the post-translational 
level. Down-regulation of either H- or K-Ras by RNA interference (RNAi) did not impair 
Erk activation by growth factors, whereas an RNAi specific for N-Ras inhibited 
activation of Erk, PKB and SCLC cell growth.  
MAIN CONCLUSION: Together our data demonstrate that inhibiting Ras signaling 
with simvastatin potently disrupts growth and survival in human SCLC cells. 
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5.  Discussion 
5.1 PI3K signaling in human cancer 
Almost twenty years after the discovery of PI3K, this family of enzymes has become the 
focus of intensive research aimed at developing new drugs for a wide variety of diseases, 
including cancer, inflammation and allergy. The discovery of the many genetic 
alterations affecting the PI3K/PTEN/Akt/mTOR pathway in human cancer has clearly 
placed some of the enzymes involved, including p110α, mTOR and Akt, on the top list of 
druggable targets in the field on oncology research. Moreover, the recognition that some 
of the molecular alterations, such as increased Akt phosphorylation or PTEN mutations 
correlate with clinical parameters, such as outcome, in cancer patients will possibly result 
in the development of new diagnostic protocols in specific types of cancer. What are the 
challenges ahead? The generic PI3K inhibitors LY294002 ad wortmannin have greatly 
facilitated the deciphering of the biological responses and signaling pathways controlled 
by PI3K and have even proved to be successful in a variety of pre-clinical models of 
human cancer. The new generations of pharmacological inhibitors with increased 
specificity for one or a restricted number of PI3K isoforms and related kinases are 
entering clinical trials. It has been demonstrated that combining these agents with 
receptor tyrosine kinase inhibitors, which have already been evaluated in clinical trials, 
can produce synergistic effects in stopping tumor growth in a variety of pre-clinical 
models. One can thus reasonably hope that these drug combinations will result in 
improved survival benefits for cancer patients. However, there remain many open 
questions related to the mechanisms governing sensitivity or resistance of tumors to these 
targeted agents. The best examples of such open questions are rapamycin and its analogs. 
There are now several reports describing potential novel mechanisms of resistance to 
these agents and there may be even more to be discovered in the future. A central 
question in the field of isoform-specific PI3K inhibitors is the question of specificity. The 
class IA PI3K catalytic isoforms have a high degree of sequence homology in their 
catalytic domains and demonstrating the specificity of the cellular effects of these agents 
remains problematic, since there are no specific readouts that discriminate betwenn these 
three enzymes. Moreover, assessing the exact expression pattern of all enzymes of the 
PI3K family in a given tumor sample remains problematic, in view of the lack of 
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availability of isoform-specific antibodies which can be used in immunohistochemistry. 
Such information is in our opinion of great importance, since there exist, in addition to 
the well-studied class I PI3K isoforms, three class II enzymes, with still poorly 
understood cellular functions, at least in human cancer. In addition, the class III PI3K 
Vps34p should also be taken into account when designing future therapies based on 
targeting PI3K isoforms, in view of its roles in autophagy and intracellular trafficking 
events. 
 
5.2 The class II PI3K family of signaling enzymes 
It is presently 10 years since the class II PI3K enzymes were cloned by different groups, 
including ours. However, the exact biological functions of these 3 enzymes (PI3KC2α, 
PI3KC2β and PI3KC2γ) remain somewhat elusive [491]. The most recent published data 
indicate a role for PI3KC2α in clathrin-mediated intracellular sorting events and ATP-
dependent priming of neurosecretory granule exocytosis [125-127, 492]. Concerning 
PI3KC2γ, its restricted tissue distribution (i.e. liver) suggests a function in hepatic 
functions and liver regeneration [104]. The most recent papers addressing the biological 
functions of PI3KC2β have described a role for this enzyme in cell migration [141-143]. 
Rac is a downstream target of this isoform in A-431 epidermal carcinoma cells, which 
provides a possible explanation for the observation by several groups that 
PI3KC2β regulates cell migration in various cell types [143]. It should be noted, 
however, that most of the published work was performed on cancer cell lines and that, in 
contrast to the results obtained in cell lines, the PI3KC2β knock-out mice displayed no 
impairment in wound healing in vivo [144]. Moreover, no obvious phenotype was 
observed in the PI3KC2β knock-out mice, in a recent paper analyzing mostly the process 
of epidermal differentiation [144]. This was in contrast to a previous report in Drosophila 
melanogaster, where ectopic expression of the class II PI3K_68D could modulate the 
process of differentiation in the wing [493]. A possible explanation for these 
discrepancies is a certain degree of redundancy in signaling by the various classes of 
PI3Ks, since only 3 enzymes (one of each class) exist in Drosophila melanogaster, while 
there are 8 known isoforms in mammals. Our observation that the expression of 
PI3KC2β is enhanced in SCLC, compared to normal lung epithelial cells [137], indicates 
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that this enzyme could play a more important role in the responses of certain cancer cells, 
as compared to normal cells.  
 
Figure 4. A simplified model of the main findings presented in papers I-IV 
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5.3 The development of targeted therapies for small cell lung cancer 
A significant increase in the understanding of the importance of RTK signaling in both 
NSCLC and SCLC biology has been achieved in the past years. In the case of NSCLC, 
targeted compounds inhibiting the EGFR have successfully achieved the transition from 
the bench to the bedside. However, the number of patients benefiting from these new 
drugs is still not as large as initially expected. The causes for this apparent lack of 
efficacy are multiple, but recent research has made a significant progress in better 
defining the conditions of optimal responsiveness to these compounds in lung cancer. 
The PI3K/Akt/mTOR pathway plays a crucial role in many aspects of tumor cell 
responses downstream of activated RTKs. Although rapamycin derivatives have not 
shown significant efficacy as single agents in either NSCLC or SCLC, their potential in 
combination with cytotoxic agents of RTK inhibitors has clearly emerged in the past 
years. In view of the multiple genetic and epigenetic aberrations found in solid tumors 
such as lung cancer and the variability in the spectrum of these alterations between 
patients, it is certainly not surprising that targeted drugs have not achieved a great 
therapeutic success so far as single agents. Combinatorial therapeutic interventions have a 
far greater potential of success, but this also depends on establishing reliable protocols to 
assess the molecular status of individual tumors with respect to the pathways that are 
being targeted. 
 
5.4 Future perspectives 
A significant effort has to be invested if one is to more definitely understand the 
individual biological functions of class II PI3Ks in normal cells, as well as in cancer 
cells. This will involve the generation of additional animal models (mouse knock-outs 
etc.) for each class II PI3K isoform, as well as the development of new isoform-specific 
pharmacological inhibitors. In collaboration with PIramed Ltd (Slough, United 
Kingdom), we have completed a first pre-clinical study of two isoform-specific inhibitors 
of PI3KC2β in a panel of human cancer cell lines, including leukemia (AML), 
neuroendocrine cancers (SCLC and neuroblastoma) and brain tumors (glioblastoma and 
medulloblastoma). These findings have been submitted for publication (Boller et al., 
Manuscript submitted). 
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Concerning our results with simvastatin in SCLC [480], future research will 
involve evaluating statins in clinical trials in SCLC patients. Indeed, a Phase III clinical 
trial has been initiated by Prof. M.J. Seckl in the United Kingdom, which is funded by 
Cancer Research UK (LungStar). This trial aims to recruit 1300 SCLC patients and 
investigate the clinical response to pravastatin in combination with chemotherapy. The 
LungStar trial was started in January 2007 and is planned to last until 2010.  
In collaboration with Prof. M.J. Seckl and other colleagues in the United 
Kingdom and Switzerland, we have also completed a pre-clinical study of the mTOR 
inhibitor RAD001 (Everolimus, Novartis) in SCLC. The results of this study have been 
submitted for publication (Marinov et al., Manuscript submitted). It should be noted, 
however, the another rapamycin derivative CCI-779 showed no activity as a single agent 
in a recent Phase I clinical trial in SCLC, the results of which were presented at the 
ASCO 2006 Meeting. Clearly, there is a need to better understand the molecular 
mechanisms controlling sensitivity/resistance of SCLC cells to these agents.  
Our group has also recently made some new contributions to the field of RTK and 
PI3K signaling in human cancer. In SCLC, we have shown that the Src family of non-
receptor tyrosine kinases couples to PI3K signaling and is required for optimal Akt 
activation and cell survival, downstream of c-Kit [494]. In neuroblastoma, we have 
evaluated the potential of a novel IGF-IR inhibitor (NVP-AEW541, Novartis) as an anti-
proliferative and cytostatic agent [495]. In this study, we have also characterized Akt as a 
major contributor to resistance to IGF-IR inhibitors in neuroblastoma [495]. In AML, we 
have, together with another group, characterized an autocrine signaling loop involving 
IGF-I and the IGF-IR in proliferation, survival and chemoresistance [496, 497]. Finally, 
in the atypical teratoid/rhabdoid tumor of the central nervous system, we have described a 
novel autocrine signaling loop involving insulin and the insulin receptor, which via the 
PI3K isoform p110α, contributes to proliferation and survival of the tumor cells [498].  
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